Stefan S. Zeuzem
#78,476
Most Influential Person Now
Stefan S. Zeuzem's AcademicInfluence.com Rankings
Stefan S. Zeuzemphilosophy Degrees
Philosophy
#2684
World Rank
#4508
Historical Rank
Logic
#715
World Rank
#1230
Historical Rank

Download Badge
Philosophy
Why Is Stefan S. Zeuzem Influential?
(Suggest an Edit or Addition)Stefan S. Zeuzem's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Sorafenib in advanced hepatocellular carcinoma. (2008) (5771)
- Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004) (2954)
- Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) (2539)
- Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. (2013) (2069)
- Treatment of HCV infection by targeting microRNA. (2013) (1981)
- Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014) (1667)
- Telaprevir for retreatment of HCV infection. (2011) (1630)
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2017) (1601)
- Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. (2012) (1468)
- Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. (2008) (1454)
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011) (1454)
- Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. (1998) (1334)
- Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis (2009) (1203)
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial (2005) (1160)
- Peginterferon alfa-2a in patients with chronic hepatitis C. (2000) (1120)
- Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. (2009) (1096)
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (2018) (1034)
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. (2015) (947)
- Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) (929)
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
- Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014) (824)
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2014) (783)
- Telaprevir for previously treated chronic HCV infection. (2010) (769)
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015) (764)
- Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. (2010) (739)
- Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. (2007) (656)
- Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. (2009) (646)
- Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. (2007) (622)
- Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C (2003) (622)
- Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis (2007) (618)
- Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. (2014) (617)
- 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. (2009) (570)
- Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. (2006) (564)
- Resistance to direct antiviral agents in patients with hepatitis C virus infection. (2010) (552)
- Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (518)
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. (2006) (509)
- Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database (2011) (503)
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. (2004) (471)
- Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta‐analysis (2012) (470)
- Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis (2015) (455)
- Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (2017) (452)
- Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. (2006) (428)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C (2005) (425)
- Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. (2005) (410)
- Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients (2007) (410)
- Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients (2003) (387)
- Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. (2009) (375)
- Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States (2013) (358)
- A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. (2010) (358)
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients (2009) (338)
- Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. (2007) (336)
- SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. (2007) (332)
- Retroperitoneal endoscopic debridement for infected peripancreatic necrosis (2000) (332)
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
- Telbivudine versus lamivudine in patients with chronic hepatitis B. (2007) (322)
- GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection (2015) (321)
- Antiviral strategies in hepatitis C virus infection. (2012) (311)
- Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy (2002) (311)
- Expression of Interleukin‐12‐Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin‐23p19 and Interleukin‐27p28 in Crohn's Disease But Not in Ulcerative Colitis (2005) (304)
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. (2017) (300)
- Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. (2001) (297)
- Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study (2013) (295)
- High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial (2010) (294)
- Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? (2004) (292)
- Real-time elastography for the differentiation of benign and malignant thyroid nodules: a meta-analysis. (2010) (291)
- Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. (2014) (287)
- From non-A, non-B hepatitis to hepatitis C virus cure. (2015) (287)
- Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C (2004) (280)
- Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. (2007) (276)
- Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus (2008) (270)
- Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. (2014) (268)
- Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C (2007) (266)
- Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo (1996) (265)
- Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon (2003) (264)
- Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function (2009) (261)
- Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma (1999) (257)
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis (2015) (256)
- Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study (2006) (253)
- Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. (2014) (252)
- The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. (2015) (251)
- HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality (2009) (249)
- Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. (2004) (249)
- Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results (2007) (237)
- Faldaprevir and deleobuvir for HCV genotype 1 infection. (2013) (234)
- Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data (2004) (234)
- Expert opinion on the treatment of patients with chronic hepatitis C (2009) (232)
- Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. (2006) (230)
- IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection (2006) (225)
- Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. (2005) (222)
- Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta (2014) (217)
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. (2017) (216)
- Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels (2013) (216)
- Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. (2007) (216)
- Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. (1996) (212)
- New therapies for hepatitis C virus infection. (2009) (210)
- Factors that predict response of patients with hepatitis C virus infection to boceprevir. (2012) (209)
- Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. (2002) (206)
- Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. (2016) (206)
- Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. (2011) (206)
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives (2012) (204)
- NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. (2017) (204)
- Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. (2009) (203)
- Benefit of a clipping device in use in intestinal bleeding and intestinal leakage. (2011) (203)
- Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa (1997) (198)
- Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
- Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection (2011) (197)
- Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
- Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. (2013) (191)
- Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. (2012) (187)
- The way forward in HCV treatment — finding the right path (2008) (187)
- [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
- [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. (2011) (181)
- Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfa (1998) (179)
- Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover (1998) (176)
- Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. (2013) (176)
- Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C (2007) (176)
- Vitamin D deficiency and a CYP27B1–1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy (2010) (174)
- Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. (2008) (173)
- Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms (2011) (172)
- Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. (2013) (172)
- Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. (2012) (171)
- Hepatitis C pharmacogenetics: State of the art in 2010 (2011) (168)
- Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers (2013) (165)
- Pharmacokinetics of peginterferons. (2003) (164)
- Peginterferon plus adefovir versus either drug alone for hepatitis delta. (2011) (163)
- International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. (2005) (162)
- New kinetic models for the hepatitis C virus (2005) (160)
- Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. (2015) (157)
- Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. (2008) (157)
- Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. (2014) (156)
- Regression of fibrosis and portal hypertension in HCV‐associated cirrhosis and sustained virologic response after interferon‐free antiviral therapy (2016) (151)
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. (2016) (151)
- The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis (2013) (149)
- Expression and Release of IL-18 Binding Protein in Response to IFN-γ1 (2001) (149)
- Detection of residual hepatitis C virus RNA by transcription‐mediated amplification in patients with complete virologic response according to polymerase chain reaction–based assays (2000) (149)
- The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120). (2020) (146)
- Impact of COVID-19 on global HCV elimination efforts (2020) (141)
- Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. (2011) (140)
- Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C (2010) (138)
- A new standard of care for the treatment of chronic HCV infection (2011) (137)
- Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study (2014) (135)
- Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials (2015) (135)
- Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis (2010) (133)
- Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). (2002) (133)
- Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histolog (1996) (132)
- Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. (2011) (131)
- Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma (2011) (131)
- Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. (2019) (131)
- Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. (2006) (129)
- Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge (2013) (128)
- The way forward in HCV treatment — finding the right path (2007) (127)
- Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. (2009) (127)
- Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification (2008) (126)
- Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. (2011) (126)
- Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. (2011) (126)
- Predicted effects of treatment for HCV infection vary among European countries. (2012) (126)
- Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine (2006) (126)
- Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. (2018) (126)
- The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C (2012) (125)
- Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients (2013) (125)
- Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. (2005) (123)
- Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. (2017) (119)
- A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
- Serum microRNA‐122 levels in different groups of patients with chronic hepatitis B virus infection (2012) (117)
- Prevalence of hepatitis C virus antibodies and evaluation of hepatitis C virus genotypes in patients with lichen planus. (1997) (116)
- Meta‐analysis: the outcome of anti‐viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis (2008) (115)
- Acoustic Radiation Force Impulse-Imaging for the evaluation of the thyroid gland: a limited patient feasibility study. (2012) (115)
- Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. (1998) (115)
- IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. (2011) (114)
- Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. (2017) (114)
- IL28B single nucleotide polymorphisms in the treatment of hepatitis C. (2011) (113)
- Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (2013) (113)
- Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. (2012) (112)
- Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success (2012) (112)
- Dynamics of hepatitis B virus infection in vivo. (1997) (112)
- Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. (2013) (111)
- Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy (2010) (110)
- Acoustic Radiation Force Impulse Imaging for Differentiation of Thyroid Nodules (2012) (109)
- A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care (2013) (109)
- Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5 (2006) (109)
- Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. (2008) (108)
- Contrast‐Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a meta‐analysis (2013) (108)
- Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. (2011) (107)
- Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. (2016) (107)
- Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. (2017) (106)
- Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis (2010) (105)
- Hepatitis C Virus Kinetics (1999) (105)
- The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. (2008) (104)
- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (2022) (103)
- Perspectives and challenges of interferon-free therapy for chronic hepatitis C. (2013) (103)
- A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. (2000) (102)
- Emerging therapies for the treatment of hepatitis C (2013) (101)
- Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. (2014) (100)
- Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. (2018) (100)
- Occult hepatitis C: How convincing are the current data? (2009) (100)
- Tumor regression by combination antisense therapy against Plk1 and Bcl-2 (2003) (99)
- Chronic hepatitis C in patients with persistently normal alanine transaminase levels. (2006) (98)
- PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. (2020) (98)
- Allosteric activation of the protein kinase PDK1 with low molecular weight compounds (2006) (98)
- Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis (2019) (98)
- Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. (2014) (97)
- Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection (2012) (97)
- Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis (2010) (97)
- Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis C (1997) (95)
- Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials (2012) (95)
- The new paradigm of hepatitis C therapy: integration of oral therapies into best practices (2013) (95)
- Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. (2014) (94)
- Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. (2014) (94)
- Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. (2014) (94)
- Cyclic AMP Induces Transactivation of the Receptors for Epidermal Growth Factor and Nerve Growth Factor, Thereby Modulating Activation of MAP Kinase, Akt, and Neurite Outgrowth in PC12 Cells* (2002) (94)
- Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis (2015) (93)
- Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. (2017) (92)
- Market uptake of new antiviral drugs for the treatment of hepatitis C. (2008) (91)
- Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients (2013) (91)
- Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms (2008) (89)
- Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers (2010) (88)
- Randomized, double‐blind, placebo‐controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C (2000) (88)
- Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. (2016) (88)
- A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis (2003) (88)
- Assessment of liver fibrosis with 2-D shear wave elastography in comparison to transient elastography and acoustic radiation force impulse imaging in patients with chronic liver disease. (2015) (86)
- High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. (2013) (86)
- Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3 (2011) (85)
- Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. (2010) (85)
- Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin (2010) (84)
- Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C (2008) (84)
- Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis (2012) (83)
- 13C‐methacetin breath test as liver function test in patients with chronic hepatitis C virus infection (2005) (83)
- Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection (2007) (83)
- Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. (2007) (82)
- Capnographic monitoring of propofol-based sedation during colonoscopy (2013) (82)
- Intravesicular acidification correlates with binding of ADP-ribosylation factor to microsomal membranes. (1992) (82)
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
- Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. (2013) (82)
- Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy (2011) (81)
- IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy (2011) (81)
- Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). (2016) (80)
- Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus (2008) (80)
- Bethesda Guidelines: Relation to Microsatellite Instability and MLH1 Promoter Methylation in Patients with Colorectal Cancer (2001) (80)
- The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection (2016) (79)
- Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. (2000) (79)
- A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants (2010) (79)
- 5′-CpG island methylation of theLKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer (2000) (79)
- Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. (2006) (78)
- Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen‐positive chronic hepatitis B (2012) (78)
- 12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY (2011) (78)
- Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays (1996) (78)
- Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. (2002) (78)
- Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. (2015) (77)
- Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. (1999) (77)
- Bacterial infection‐triggered acute‐on‐chronic liver failure is associated with increased mortality (2018) (77)
- Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats (2004) (77)
- HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). (2007) (76)
- Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease. (2009) (76)
- Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. (2013) (75)
- Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. (2006) (75)
- Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. (2007) (75)
- Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study (2016) (75)
- Severe 25‐hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma – a prospective cohort study (2014) (75)
- Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients (2006) (74)
- The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation (2005) (74)
- Cholecystokinin Stimulates Extracellular Signal-regulated Kinase through Activation of the Epidermal Growth Factor Receptor, Yes, and Protein Kinase C (2003) (74)
- Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity (2012) (73)
- Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C (2010) (72)
- Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. (2009) (71)
- Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. (2019) (71)
- Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. (2002) (71)
- Triple therapy with amantadine in treatment‐naive patients with chronic hepatitis C: A placebo‐controlled trial (2003) (70)
- Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients (2015) (70)
- Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response (2006) (70)
- Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. (1998) (69)
- DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. (2020) (69)
- Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study (2011) (69)
- Acoustic radiation force impulse imaging for non‐invasive assessment of liver fibrosis in chronic hepatitis B (2013) (68)
- Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. (2013) (68)
- Serum MicroRNA-122 Predicts Survival in Patients with Liver Cirrhosis (2012) (68)
- Sofosbuvir and Velpatasvir Combination Improves Patient‐reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis (2016) (68)
- Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients (1997) (68)
- Interobserver Agreement of Thyroid Imaging Reporting and Data System (TIRADS) and Strain Elastography for the Assessment of Thyroid Nodules (2013) (68)
- Multiple plastic stents versus covered metal stent for treatment of anastomotic biliary strictures after liver transplantation: a prospective, randomized, multicenter trial. (2017) (68)
- Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. (2016) (67)
- Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. (2011) (67)
- An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo (2004) (67)
- Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. (2009) (67)
- Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a (2008) (67)
- 13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY (2011) (66)
- Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease (2012) (66)
- Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. (2009) (66)
- Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response (2011) (66)
- High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients (2012) (65)
- Real-time elastography and contrast-enhanced ultrasound for the assessment of thyroid nodules. (2009) (65)
- Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. (2013) (65)
- 101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2 (2012) (65)
- Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses (2002) (65)
- Review article: predicting response in hepatitis C virus therapy (2006) (65)
- BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors (2005) (65)
- Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus. (1994) (65)
- Ribavirin: current role in the optimal clinical management of chronic hepatitis C. (2009) (64)
- Current and future treatment options for HCV. (2009) (63)
- Allosteric regulation of protein kinase PKCζ by the N‐terminal C1 domain and small compounds to the PIF‐pocket (2011) (63)
- [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
- Mutations in the MutSα interaction interface of MLH1 can abolish DNA mismatch repair (2006) (62)
- Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification (2019) (62)
- A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C (2012) (62)
- Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. (2016) (62)
- Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients (2009) (61)
- Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype (2012) (61)
- Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. (2012) (61)
- Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. (2013) (60)
- 3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY (2013) (60)
- PD‐L1 expression in extrahepatic cholangiocarcinoma (2017) (59)
- 58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION (2012) (59)
- The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis (2016) (59)
- Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis. (2008) (59)
- LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY (2010) (59)
- Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants (2002) (58)
- Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. (2010) (58)
- Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. (2015) (57)
- Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. (2016) (57)
- Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. (2013) (57)
- Risk factors for the transmission of hepatitis C. (1996) (57)
- 1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS (2012) (56)
- Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids (2018) (56)
- New therapeutic strategies in HCV: polymerase inhibitors (2013) (56)
- Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. (2004) (56)
- Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy (2008) (56)
- Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis (2015) (55)
- Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. (2011) (55)
- Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data (2011) (55)
- Contrast-enhanced sonography of adrenal masses: differentiation of adenomas and nonadenomatous lesions. (2008) (54)
- N‐terminus of hMLH1 confers interaction of hMutLα and hMutLβ with hMutSα (2003) (54)
- Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity (2006) (54)
- Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase. (2016) (54)
- Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin (2012) (54)
- Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy (2005) (54)
- Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. (2000) (54)
- 1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL (2013) (54)
- 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
- Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. (2015) (53)
- Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. (2003) (53)
- Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. (2014) (53)
- ERCP in elderly patients: increased risk of sedation adverse events but low frequency of post-ERCP pancreatitis. (2015) (53)
- Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis (2021) (53)
- Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. (2008) (53)
- A phase I/II study of recombinant human interleukin‐12 in patients with chronic hepatitis C (1999) (52)
- Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma. (2012) (52)
- Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®). (2012) (52)
- Serum sphingolipidomic analyses reveal an upregulation of C16- ceramide and sphingosine-1-phosphate in hepatocellular carcinoma (2016) (52)
- Serum Autotaxin Is a Parameter for the Severity of Liver Cirrhosis and Overall Survival in Patients with Liver Cirrhosis – A Prospective Cohort Study (2014) (52)
- Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon α-2a (2001) (52)
- Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. (2006) (51)
- O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY (2014) (51)
- Severity of HCV-Induced Liver Damage Alters Glucose Homeostasis in Noncirrhotic Patients with Chronic HCV Infection (2000) (51)
- Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (51)
- 4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS (2011) (51)
- Clinical implications of hepatitis C viral kinetics. (1999) (51)
- Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. (2011) (51)
- Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life (2006) (50)
- Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b (2012) (50)
- Photoallergic skin reaction to ribavirin (1999) (50)
- Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. (2011) (50)
- Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study (2012) (50)
- Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. (2014) (50)
- P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV (2015) (50)
- Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response (2017) (49)
- No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. (2018) (49)
- 1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN (2012) (49)
- An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa‐2b combination therapy for chronic hepatitis C (2009) (49)
- Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. (2017) (49)
- Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C (2005) (49)
- Gut-liver axis (2000) (49)
- 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
- Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. (2001) (48)
- Involvement of the platelet‐derived growth factor receptor in angiotensin II‐induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells (2000) (48)
- O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY (2014) (48)
- Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. (2003) (48)
- Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. (1997) (48)
- Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis (2018) (48)
- Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. (2004) (48)
- 8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS (2011) (47)
- Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response (2000) (47)
- Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. (2011) (47)
- PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients (2013) (47)
- Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. (2017) (47)
- Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial (2012) (47)
- Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope (2011) (47)
- Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. (2005) (47)
- 484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (46)
- p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. (1996) (46)
- Is there sufficient evidence to recommend antiviral therapy in hepatitis C? (2014) (46)
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. (2015) (46)
- Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C (2005) (46)
- 58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY (2008) (45)
- [8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE? (2007) (45)
- Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution (2011) (45)
- Thymosin beta 4 expression and nuclear transport are regulated by hMLH1. (2007) (45)
- A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers (2012) (45)
- Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis (2017) (44)
- Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease (2004) (44)
- Interferon lambda 4 genotypes and resistance‐associated variants in patients infected with hepatitis C virus genotypes 1 and 3 (2016) (44)
- Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent (2013) (44)
- Anemia Had No Effect on Efficacy Outcomes in Treatment-NaïVE Patients Who Received Telaprevir-Based Regimen in the Advance and Illuminate Phase 3 Studies (2011) (44)
- Superiority of Interferon-Free Regimens for Chronic Hepatitis C (2017) (44)
- RNAse A‐like enzymes in serum inhibit the anti‐neoplastic activity of siRNA targeting polo‐like kinase 1 (2007) (43)
- Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. (2005) (43)
- 481 THE EFFICIENCY OF ACOUSTIC RADIATION FORCE IMPULSE-IMAGING FOR THE STAGING OF LIVER FIBROSIS: A META-ANALYSIS (2013) (43)
- 869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial (2013) (43)
- Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital (2018) (43)
- Rapid decrease of wild-type hepatitis C virus on telaprevir treatment (2008) (43)
- Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. (2012) (43)
- Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. (2012) (43)
- Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptors. (2004) (43)
- Differentiation between benign and malignant adrenal mass using contrast-enhanced ultrasound. (2010) (43)
- Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. (2005) (43)
- New developments in HCV therapy (2012) (43)
- Long‐term effectiveness and cost‐effectiveness of antiviral treatment in hepatitis C (2010) (43)
- Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. (2017) (42)
- Viral dynamics in chronic hepatitis B patients during lamivudine therapy. (2002) (42)
- Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. (2019) (42)
- [Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results]. (2007) (42)
- P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program (2015) (42)
- Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta (2014) (42)
- CCK, carbachol, and bombesin activate distinct PLC-beta isoenzymes via Gq/11 in rat pancreatic acinar membranes. (1997) (42)
- How to use virological tools for the optimal management of chronic hepatitis C (2011) (42)
- [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. (2018) (42)
- Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. (2012) (41)
- The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection (2018) (41)
- Contrast‐enhanced ultrasound in the diagnosis of malignant mesenchymal liver tumors (2010) (41)
- Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. (2016) (41)
- Perihepatic lymph nodes as a marker of antiviral response in patients with chronic hepatitis C infection. (2000) (41)
- Long‐term follow‐up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation (2013) (41)
- The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection (2016) (41)
- Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. (2010) (40)
- Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. (2016) (40)
- Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. (2014) (40)
- Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. (2011) (39)
- A de novo deletion of chromosome 5q causing familial adenomatous polyposis, dysmorphic features, and mild mental retardation (2001) (39)
- The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. (2009) (39)
- Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (2004) (39)
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis (2015) (39)
- Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. (2020) (39)
- Serum microRNA‐122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy (2013) (38)
- Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. (1997) (38)
- Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. (2002) (38)
- Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C (2003) (38)
- Human colon organoids reveal distinct physiologic and oncogenic Wnt responses (2019) (38)
- mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. (2011) (38)
- 477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES (2011) (38)
- Evaluation of a reverse hybridization assay for genotyping of hepatitis C virus. (1995) (37)
- Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study (2012) (37)
- Phylogenetic analysis of hepatitis C virus isolates from hemodialysis patients. (1996) (37)
- Structural and functional comparison of the non-structural protein 4B in flaviviridae. (2007) (37)
- 106 International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (copegus®) (2003) (37)
- Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. (2000) (37)
- Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. (1996) (37)
- 1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY (2009) (37)
- N-terminus of hMLH1 confers interaction of hMutLalpha and hMutLbeta with hMutSalpha. (2003) (36)
- Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels (2004) (36)
- 5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN (2011) (36)
- No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct‐acting antivirals for hepatitis C in a large real‐world cohort (2017) (36)
- Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection (2015) (36)
- Insulin secretion, adipocyte insulin binding and insulin sensitivity in thyrotoxicosis. (1985) (36)
- Placebo‐controlled trial of 400 mg amantadine combined with peginterferon alfa‐2a and ribavirin for 48 weeks in chronic hepatitis C virus‐1 infection (2008) (36)
- Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters (2014) (36)
- Interleukin-12 in the treatment of chronic hepatitis B and C. (2001) (36)
- Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals (2018) (36)
- Interferon alfa down‐regulates CD81 in patients with chronic hepatitis C (2001) (36)
- 52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B (2013) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography (2013) (35)
- Promoter Methylation of MLH1, PMS2, MSH2 and p16 Is a Phenomenon of Advanced-Stage HCCs (2014) (35)
- Cost‐effective and safe ambulatory long‐term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation (2003) (35)
- Quantification of hepatitis C virus RNA by competitive reverse transcription and polymerase chain reaction using a modified hepatitis C virus RNA transcript. (1995) (35)
- A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection (2008) (35)
- Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis (2013) (34)
- Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy (2001) (34)
- Peutz-Jeghers syndrome: molecular analysis of a three-generation kindred with a novel defect in the serine threonine kinase gene STK11 (1999) (34)
- Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). (2021) (34)
- Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results (2013) (34)
- hMutSα forms an ATP-dependent complex with hMutLα and hMutLβ on DNA (2002) (34)
- Forewarned is forearmed. (2009) (34)
- Characterization of putrescine transport across the intestinal epithelium: study using isolated brush border and basolateral membrane vesicles of the enterocyte (1995) (34)
- Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors (2018) (34)
- Polo-like kinase1, a new target for antisense tumor therapy. (2000) (34)
- Peri-hepatic lymphadenopathy in primary biliary cirrhosis reflects progression of the disease. (1999) (33)
- Regulation of the Interaction between Protein Kinase C-related Protein Kinase 2 (PRK2) and Its Upstream Kinase, 3-Phosphoinositide-dependent Protein Kinase 1 (PDK1)* (2009) (33)
- Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients (2018) (33)
- Impaired health‐related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels (2006) (33)
- Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis (2015) (33)
- Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C (2011) (33)
- 3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma (2007) (33)
- Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus (2015) (33)
- Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. (2004) (33)
- DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4 (2015) (33)
- Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies (2018) (33)
- 2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL (2012) (32)
- Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. (1996) (32)
- 734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial (2006) (32)
- Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. (2020) (32)
- Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity (2011) (32)
- GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. (2005) (32)
- Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C (2009) (32)
- Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations (2015) (32)
- Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (2013) (31)
- Randomized, placebo‐controlled, double‐blind trial with interferon‐α with and without amantadine sulphate in primary interferon‐α nonresponders with chronic hepatitis C (2001) (31)
- Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018. (2019) (31)
- Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study (2018) (31)
- Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging. (2014) (31)
- T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study (2012) (31)
- Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial: 487 (2013) (31)
- Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection (2018) (31)
- Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1. (2000) (31)
- Limited Value of Fluorine-18-Fluorodeoxyglucose PET for the Differential Diagnosis of Focal Liver Lesions in Patients with Chronic Hepatitis C Virus Infection (1998) (31)
- MUTYH gene expression and alternative splicing in controls and polyposis patients (2012) (31)
- Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061 (2005) (31)
- 1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES (2012) (30)
- Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV–HCV Coinfection and Advanced Liver Disease (2016) (30)
- Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. (2009) (30)
- Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. (2014) (30)
- Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) (2015) (30)
- Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation (2010) (30)
- Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. (2017) (30)
- Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. (2015) (30)
- 1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT (2011) (29)
- Intratumoral heterogeneity of intrahepatic cholangiocarcinoma (2017) (29)
- A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation (2016) (29)
- Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response (2009) (29)
- First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report (2021) (29)
- Retreatment of Patients who Failed Daa-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database (2016) (29)
- Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. (2014) (29)
- Thursday, 24 AprilParallel Session 1: HEPATITIS C THERAPY7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (29)
- Predictive value of mucosal TNF‐&agr; transcripts in steroid‐refractory Crohn's disease patients receiving intensive immunosuppressive therapy (2007) (29)
- Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity (2006) (29)
- Molecular detection of thyroid cancer: an update (2004) (29)
- Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. (1998) (29)
- Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture (1999) (28)
- Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. (2005) (28)
- The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far. (2022) (28)
- Development of sofosbuvir for the treatment of hepatitis C virus infection (2015) (28)
- Effects of prostaglandins and indomethacin on gastric emptying in the rat. (1994) (28)
- The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection (2011) (28)
- Single measurement of hemoglobin predicts outcome of HCC patients (2013) (28)
- Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients (2009) (27)
- Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study (2015) (27)
- Telaprevir for the treatment of hepatitis C (2012) (27)
- Peginterferon α-2a (40kD) [Pegasys®] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon®-A] (2012) (27)
- Evaluation of 2D- Shear Wave Elastography for Characterisation of Focal Liver Lesions. (2017) (27)
- Pan-intestinal capsule endoscopy in patients with postoperative Crohn's disease: a pilot study (2017) (27)
- Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition (2017) (27)
- Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study (2015) (27)
- Evaluation of the safety and efficacy of once-weekly PEG/interferon alfa-2A (PEGASYS™) for chronic hepatitis C. A multinational, randomized study (2000) (27)
- New Antiviral Therapies in the Management of HCV Infection (2012) (27)
- Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS (2019) (27)
- Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1 (2014) (27)
- Prevalence and clinical and histological manifestation of hepatitis G/GBV-C infections in patients with elevated aminotransferases of unknown etiology. (1997) (26)
- Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor. (2003) (26)
- Optimal therapy in genotype 1 patients (2009) (26)
- Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. (2009) (26)
- Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-α2A Treatment (2012) (26)
- 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
- Clinical relevance of HCV antiviral drug resistance. (2012) (26)
- Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. (2012) (26)
- Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C (2014) (26)
- The Periprocedural Management of Anticoagulation and Platelet Aggregation Inhibitors in Endoscopic Interventions. (2016) (26)
- Dynamics of hepatitis C virus infection. (2002) (26)
- Interferon-based therapy for chronic hepatitis C: current and future perspectives (2008) (25)
- Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion (2020) (25)
- [S3 guideline hepatitis C addendum]. (2015) (25)
- Activation of a cryptic splice site of PTEN and loss of heterozygosity in benign skin lesions in Cowden disease. (2001) (25)
- Early Viral Kinetics of Telbivudine and Entecavir: Results of a 12-Week Randomized Exploratory Study with Patients with HBeAg-Positive Chronic Hepatitis B (2009) (25)
- Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon‐free treatment in the SOUND‐C2 study (2013) (25)
- Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-&agr;-2a and ribavirin (2010) (25)
- 740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS (2011) (25)
- Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging. (2015) (25)
- T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study (2012) (25)
- Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018) (2021) (25)
- Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. (2016) (25)
- 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION (2011) (25)
- Regulation of Protein Kinase C-related Protein Kinase 2 (PRK2) by an Intermolecular PRK2-PRK2 Interaction Mediated by Its N-terminal Domain* (2012) (24)
- OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients (2013) (24)
- 737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a (2006) (24)
- Screening for IL28B gene variants identifies predictors of hepatitis C therapy success (2010) (24)
- Triple therapy with telaprevir: results in hepatitis C virus‐genotype 1 infected relapsers and non‐responders (2012) (24)
- IL‐22 and IL‐22‐Binding Protein Are Associated With Development of and Mortality From Acute‐on‐Chronic Liver Failure (2019) (24)
- Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir (2017) (24)
- Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification (2018) (24)
- Multicenter Performance Evaluation of a New TaqMan PCR Assay for Monitoring Human Immunodeficiency Virus RNA Load (2006) (24)
- The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
- Prevalence of colorectal cancer and its precursor lesions in symptomatic and asymptomatic patients undergoing total colonoscopy: results of a large prospective, multicenter, controlled endoscopy study (2013) (24)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus (2010) (24)
- Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients. (2014) (24)
- Current standards in the treatment of chronic hepatitis C. (2012) (24)
- The complex interrelationships between chronic lung and liver disease: a review (2010) (24)
- Quantification of fecal carbohydrates by near-infrared reflectance analysis. (1996) (23)
- EGF Stimulates Polyamine Uptake in Caco-2 Cells (1995) (23)
- ACE2, the Receptor that Enables Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators (2020) (23)
- Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. (2006) (23)
- Treatment Options in Hepatitis C. (2017) (23)
- Subcellular distribution and function of Rab3A-D in pancreatic acinar AR42J cells. (2001) (23)
- C-Terminal Fluorescent Labeling Impairs Functionality of DNA Mismatch Repair Proteins (2012) (23)
- Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. (2013) (23)
- Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial (2014) (23)
- Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid‐Reducing Agents in Patients With Chronic HCV Infection (2019) (22)
- Intraductal biopsies in indeterminate biliary stricture: Evaluation of histopathological criteria in fluoroscopy- vs. cholangioscopy guided technique. (2016) (22)
- Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies (2014) (22)
- Endoscopic transhiatal drainage of a mediastinal pancreatic pseudocyst. (2006) (22)
- Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. (2014) (22)
- Serum Tests for Diagnosis and Follow-Up of Hepatocellular Carcinoma after Treatment (1998) (22)
- P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (2015) (22)
- Indication for ‘Over the Scope’ (OTS)-Clip vs. Covered Self-Expanding Metal Stent (cSEMS) Is Unequal in Upper Gastrointestinal Leakage: Results from a Retrospective Head-to-Head Comparison (2015) (22)
- Do differences in pegylation of interferon alfa matter? (2010) (22)
- [Analysis of hepatic echo patterns in chronic hepatitis C]. (1999) (22)
- Novel hepatitis C drugs in current trials. (2008) (22)
- Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease (2021) (22)
- Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. (2012) (22)
- Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND‐C3, a Phase 2b study (2015) (22)
- Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers (2012) (22)
- Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure (2017) (21)
- 85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) (2009) (21)
- Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. (2020) (21)
- Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. (2011) (21)
- The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infection (2014) (21)
- Mutations in the putative HCV‐E2 CD81 binding regions and correlation with cell surface CD81 expression (2004) (21)
- Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response (2010) (21)
- The kinetics of hepatitis C virus infection. (2001) (21)
- Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. (2005) (21)
- Polymorphisms of HLA‐DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B (2014) (21)
- Retreatment with Interferon-Alpha and Ribavirin in Primary Interferon-Alpha Non-Responders with Chronic Hepatitis C (2000) (21)
- The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients (2016) (21)
- Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors (2018) (21)
- 881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS (2013) (21)
- FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. (2011) (21)
- An Interstitial Deletion at 3p21.3 Results in the Genetic Fusion of MLH1 and ITGA9 in a Lynch Syndrome Family (2009) (21)
- Probiotic Lactobacillus casei Shirota improves kidney function, inflammation and bowel movements in hospitalized patients with acute gastroenteritis – A prospective study (2015) (20)
- [Ultrasound lymph node imaging in the abdomen and retroperitoneum of healthy probands]. (1998) (20)
- 78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysis (2006) (20)
- EGF stimulates polyamine uptake in Caco-2 cells. (1995) (20)
- Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. (2003) (20)
- Absence of the interstitial cell of Cajal network in mitochondrial neurogastrointestinal encephalomyopathy (2009) (20)
- [4] 72 WEEK DATA OF THE HIDIT-1 TRIAL: A MULTICENTER RANDOMISED STUDY COMPARING PEGINTERFERON α-2a PLUS ADEFOVIR VS. PEGINTERFERON α-2a PLUS PLACEBO VS. ADEFOVIR IN CHRONIC DELTA HEPATITIS (2007) (20)
- 4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR (2010) (20)
- Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy. (2000) (20)
- Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection (2014) (20)
- Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. (2013) (20)
- Subanalyses of the Telaprevir Lead-in ARM in the Realize Study: Response at Week 4 is Not a Substitute for Prior Null Response Categorization (2011) (20)
- Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies (2015) (20)
- The economics of treating chronic hepatitis C patients with peginterferon α‐2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase * (2006) (20)
- Selective targeting of tumor associated macrophages in different tumor models (2018) (20)
- Analysis of the human MutLα·MutSα complex (2006) (20)
- A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment (2020) (20)
- Current therapy for hepatitis C (2007) (20)
- Fulminant hepatitis A in a patient with severe hyperthyroidism: rapid recovery from hepatic coma after plasmapheresis and total thyroidectomy. (2000) (20)
- Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low‐to‐moderate genetic barrier nucleoside analogs (2013) (20)
- Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma (2013) (20)
- BAX and caspase-5 frameshift mutations and spontaneous apoptosis in colorectal cancer with microsatellite instability (2004) (20)
- Heterosexual transmission of GB virus-C/hepatitis G virus infection. (1997) (20)
- Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs (2020) (20)
- 12 Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV (2006) (20)
- 12 DETECTION OF RESISTANT VARIANTS IN THE HEPATITIS C VIRUS NS3 PROTEASE GENE BY CLONAL SEQUENCING AT LONG-TERM FOLLOW-UP IN PATIENTS TREATED WITH BOCEPREVIR (2009) (19)
- DNA mismatch repair and Lynch syndrome (2006) (19)
- Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. (2007) (19)
- The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses (2017) (19)
- 65 CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS TREATED WITH BOCEPREVIR (SCH503034) (2008) (19)
- Cystic adrenal lymphangioma: incidental diagnosis on abdominal sonography. (2000) (19)
- Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin (2012) (19)
- STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. (2015) (19)
- Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates (2021) (19)
- Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. (2012) (19)
- Tyrphostins inhibit secretagogue-induced 1,4,5-IP3 production and amylase release in pancreatic acini. (1994) (19)
- Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry (2018) (19)
- Liver transplantation for chronic hepatitis C virus infection in the United States 2002–2014: An analysis of the UNOS/OPTN registry (2017) (19)
- Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. (2013) (19)
- Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study (2017) (19)
- Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease (2018) (19)
- Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study. (2013) (18)
- Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. (2012) (18)
- [Standard treatment of acute and chronic hepatitis C]. (2004) (18)
- Differential expression of Rab3 isoforms during differentiation of pancreatic acinar cell line AR42J. (1997) (18)
- 250 24 weeks of monotherapy with pegylated interferon alfa-2B in patients with acute hepatitis C (2003) (18)
- The kinetics of hepatitis C virus (2006) (18)
- SEMS vs cSEMS in duodenal and small bowel obstruction: high risk of migration in the covered stent group. (2013) (18)
- 911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS (2009) (18)
- Cytoskeletal scaffolding proteins interact with Lynch‐Syndrome associated mismatch repair protein MLH1 (2010) (18)
- Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease (2008) (18)
- Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer (2019) (18)
- Reproducibility and limitations of transient elastography (2009) (18)
- Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (2020) (18)
- Patatin‐like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events (2018) (18)
- Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis (2018) (18)
- 1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS (2009) (18)
- Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin (2011) (17)
- Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients (2014) (17)
- Tivantinib in hepatocellular carcinoma (2013) (17)
- Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound. (2014) (17)
- Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon‐alpha‐based therapy in HCV‐1b‐infected patients (2007) (17)
- Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection (2014) (17)
- Real‐world experience with daclatasvir plus sofosbuvir ± ribavirin for post‐liver transplant HCV recurrence and severe liver disease (2017) (17)
- Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin (2007) (17)
- Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response (2019) (17)
- hMutSalpha forms an ATP-dependent complex with hMutLalpha and hMutLbeta on DNA. (2002) (17)
- DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin (2002) (17)
- Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. (2003) (17)
- Will interferon-free regimens prevail? (2012) (17)
- Characterization of the nuclear import of human MutLalpha. (2005) (17)
- [Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests]. (2008) (17)
- Hepatitis C Virus: A European Perspective. (2015) (17)
- [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. (2019) (17)
- PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C (2014) (17)
- Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families (2011) (17)
- Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. (2008) (16)
- MUTYH hotspot mutations in unselected colonoscopy patients (2011) (16)
- 1420 THE EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF BI201335 AND BI207127 IN GENOTYPE 1 HCV PATIENTS WITH CIRRHOSIS - INTERIM ANALYSIS FROM SOUND-C2 (2012) (16)
- Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis (2020) (16)
- Camptothecin and its analog SN‐38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE (2017) (16)
- Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care? (2008) (16)
- Duodenal angiolipoma -- endoscopic diagnosis and therapy. (2004) (16)
- Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-&agr; and ribavirin: results from a randomized, placebo-controlled, double-blind trial (2007) (16)
- 425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS (2011) (16)
- 1404 DIAGNOSIS, PREVALENCE, AND PROGNOSIS OF ACUTE-ON- CHRONIC LIVER FAILURE (ACLF): RESULTS OF THE EASL-CHRONIC LIVER FAILURE (CLIF) CONSORTIUM CANONIC STUDY (2012) (16)
- S1179 Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study (2022) (16)
- Nodular regenerative hyperplasia of the liver: a rare differential diagnosis of cholestasis with response to ursodeoxycholic acid. (2003) (16)
- Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency (2005) (16)
- Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. (2016) (16)
- Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (2020) (16)
- 9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (16)
- Eosinophilic cholangitis is a potentially underdiagnosed etiology in indeterminate biliary stricture (2017) (16)
- 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION (2010) (16)
- 964 INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN (2009) (16)
- Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin (2013) (16)
- High- and Small-Molecular-Weight GTP-Binding Proteins in Zymogen Granule Membranes of Rat Pancreatic Acinar Cells (1992) (16)
- What is (cost) effective in patients with chronic hepatitis C virus infection? (2001) (16)
- Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. (2000) (16)
- Phosphorylation‐dependent signaling controls degradation of DNA mismatch repair protein PMS2 (2017) (16)
- Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels (2016) (16)
- European Ravs Database: Frequency and Characteristics of Ravs in Treatment-Naïve and DAA-Experienced Patients (2016) (16)
- Epidermal growth factor activates phospholipase C-gamma 1 via G(i)1-2 proteins in isolated pancreatic acinar membranes. (1997) (15)
- Efficacy and Safety of Sorafenib in Advanced Hepatocellular Carcinoma Under Daily Practice Conditions (2010) (15)
- [Mediastinal lymphadenopathy: an extrahepatic manifestation of chronic hepatitis C?]. (2000) (15)
- Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1-2 proteins in pancreatic acinar membranes. (1996) (15)
- Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper (2010) (15)
- α-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C (1995) (15)
- Interferon‐free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study (2016) (15)
- Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue (2014) (15)
- Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. (2004) (15)
- Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. (2009) (15)
- The hepatitis C virus NS5A protein and response to interferon α: mutational analyses in patients with chronic HCV genotype 3a infection from India (2007) (15)
- EGF inhibits secretagogue-induced cAMP production and amylase secretion by Gi proteins in pancreatic acini. (1995) (15)
- Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. (2018) (15)
- Vesicle-associated microRNAs are released from blood cells on incubation of blood samples. (2016) (15)
- Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment (2017) (15)
- HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. (2010) (15)
- Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. (1999) (15)
- Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. (2007) (15)
- Epidermal growth factor inhibits bombesin-induced activation of phospholipase C-beta1 in rat pancreatic acinar cells. (1997) (15)
- G07 : The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/ elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection (2015) (15)
- Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. (2011) (14)
- Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study (2020) (14)
- Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis (2018) (14)
- Beat-to-beat variation of heart rate in diabetic patients with autonomic neuropathy and in completely cardiac denervated patients following orthotopic heart transplantation. (1991) (14)
- Evaluation of rapid microsatellite analysis of paraffin-embedded specimens in screening for hereditary nonpolyposis colorectal cancer. (1999) (14)
- Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (14)
- HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment (2010) (14)
- Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a (2008) (14)
- An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms. (2017) (14)
- A CRM1‐dependent nuclear export pathway is involved in the regulation of MutLα subcellular localization (2011) (14)
- Cognition in hepatitis C patients treated with pegylated interferon (2009) (14)
- [Treatment of liver metastases of colorectal carcinoma: overview of hyperthermal ablation methods]. (2013) (14)
- Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis. (2022) (14)
- Managing hepatitis C in patients with the complications of cirrhosis (2018) (14)
- Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study (2016) (14)
- Cytokeratin 18‐based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients (2016) (14)
- Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis (2020) (14)
- The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease (2017) (14)
- Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon-α and the Protease Inhibitors Boceprevir or Telaprevir (2011) (14)
- Evaluation of the MLH1 I219V alteration in DNA mismatch repair activity and ulcerative colitis (2008) (14)
- Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
- [Viral hepatitis C]. (1995) (14)
- Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir (2015) (14)
- Dynamics of CD81 expression on lymphocyte subsets during interferon‐α‐based antiviral treatment of patients with chronic hepatitis C (2006) (14)
- Decade in review—HCV: Hepatitis C therapy—a fast and competitive race (2014) (14)
- Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B (2007) (13)
- Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes (2019) (13)
- Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure (2021) (13)
- Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis (2020) (13)
- A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data. (2011) (13)
- 1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY (2012) (13)
- T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study (2012) (13)
- Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center (2019) (13)
- [Sonographic detection of perihepatic lymph nodes: technique and clinical value]. (1999) (13)
- Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. (2011) (13)
- The Epidemiology of Acute Liver Failure. (2020) (13)
- Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin (2003) (13)
- The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care (2020) (13)
- Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. (1999) (13)
- Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct – a potential novel tool for differential diagnosis of indeterminate biliary stricture (2016) (13)
- The capsule endoscopy “suspected blood indicator” (SBI) for detection of active small bowel bleeding: no active bleeding in case of negative SBI (2014) (13)
- Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region. (2003) (12)
- Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study (2022) (12)
- Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes. (2019) (12)
- Inhibition of the Equilibrative Nucleoside Transporter 1 and Activation of A2A Adenosine Receptors by 8-(4-Chlorophenylthio)-modified cAMP Analogs and Their Hydrolytic Products* (2009) (12)
- Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study (2018) (12)
- Impact of COVID-19 on global hepatitis C elimination efforts (2020) (12)
- Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis (2013) (12)
- Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis (2013) (12)
- 1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS (2013) (12)
- Rejection quantity in kidney transplant recipients is associated with increasing intracellular interleukin-2 in CD8+ T-cells. (2014) (12)
- Future treatment options for HCV: double, triple, what is the optimal combination? (2008) (12)
- Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis (2016) (12)
- Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122 (2018) (12)
- Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18 (2016) (12)
- P476 SHORT-TERM (28-DAY) CLINICAL COURSE AND TRANSPLANT-FREE MORTALITY IN ACUTE ON CHRONIC LIVER FAILURE (ACLF); EVIDENCE FOR REVERSIBILITY OF ACLF (A STUDY FROM THE CANONIC DATABASE) (2014) (12)
- Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2019) (12)
- Colonisation with multidrug-resistant bacteria is associated with increased mortality in patients with cirrhosis (2015) (12)
- Identifying Indications for Percutaneous (PTC) vs. Endoscopic Ultrasound (EUS)- Guided „Rendezvous“ Procedure in Biliary Obstruction and Incomplete Endoscopic Retrograde Cholangiography (ERC) (2014) (12)
- The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis (2014) (12)
- Association of a 19- and a 21-kDa GTP-binding protein to pancreatic microsomal vesicles is regulated by the intravesicular pH established by a vacuolar-type H+-ATPase (1992) (12)
- Self-Expandable Metal Stent for Malignant Colonic Obstruction: Outcome in Proximal vs. Left Sided Tumor Localization (2013) (11)
- 943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial (2012) (11)
- 162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial (2008) (11)
- Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis (2014) (11)
- Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. (2017) (11)
- Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage. (2015) (11)
- [Sonographic detection of lymph nodes in the hepatoduodenal ligament]. (1997) (11)
- Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma (2019) (11)
- Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers (2021) (11)
- Dynamics of Apoptotic Activity during Antiviral Treatment of Patients with Chronic Hepatitis C (2007) (11)
- Identification of germline mutations in hereditary nonpolyposis colorectal cancer using base excision sequence scanning analysis. (1999) (11)
- Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir (2012) (11)
- GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019) (11)
- Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alfa-2a and ribavirin (2010) (11)
- Protein tyrosine phosphorylation in pancreatic acini: differential effects of VIP and CCK. (1997) (11)
- [Small bowel diverticula - unknown disease]. (2009) (11)
- Prospective follow‐up of patients with GBV‐C/HGV infection: Specific mutational patterns, clinical outcome, and genetic diversity (2000) (11)
- Interaction of caffeine-, IP3- and vanadate-sensitive Ca2+ pools in acinar cells of the exocrine pancreas (2005) (11)
- Corrigendum to “Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3” [J Hepatol 40 (2004) 939–999] (2005) (11)
- Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. (2009) (11)
- Proton MR Spectroscopy of Neurometabolites in Hepatic Encephalopathy During L-Ornithine-L-Aspartate Treatment–Results of a Pilot Study (2002) (10)
- Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection (2020) (10)
- Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia (2007) (10)
- Evaluation of MLH1 variants of unclear significance (2018) (10)
- Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma (2018) (10)
- Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events. (2019) (10)
- Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications (2016) (10)
- FOXE1 association with differentiated thyroid cancer and its progression. (2014) (10)
- Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis. (2022) (10)
- Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms (2018) (10)
- Fluorometric High-Performance Liquid Chromatography of Free Fatty Acids Using Panacyl Bromide (1993) (10)
- Treatment of chronic hepatitis C: Anticipated impact of resistance in patients treated with protease inhibitors (2009) (10)
- [Transient elastography (FibroScan) for the non-invasive assessment of liver fibrosis: current status and perspectives]. (2007) (10)
- 364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin (2015) (10)
- ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). (2010) (10)
- Peginterferon add‐on results in more HBsAg decline compared to monotherapy in HBeAg‐positive chronic hepatitis B patients (2016) (10)
- Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. (2015) (10)
- Analysis of the human MutLalpha.MutSalpha complex. (2006) (10)
- Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial (2002) (10)
- The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease (2020) (10)
- Long-term follow-up of endoscopic therapy in stenosis of the bilio-biliary anastomosis associated with orthotopic liver transplantation. (2013) (10)
- Loss of MLH1 sensitizes colon cancer cells to DNA‐PKcs inhibitor KU60648 (2017) (10)
- Prediction of nonSVR to therapy with pegylated interferon‐α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment (2010) (10)
- 594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies (2012) (10)
- On-Treatment HCV RNA in Patients with Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial (2016) (10)
- MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule123 (2014) (10)
- Quantification of hepatitis C virus RNA by RT-PCR in comparison to the branched DNA method. (1998) (9)
- Pre- and Post-Transplant Antiviral Therapy (HBV, HCV) (2016) (9)
- Predicting treatment outcome following 24 weeks peginterferon α‐2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV‐RNA at day 0, day 22, day 29, and week 6 (2007) (9)
- A synthetic peptide of the effector domain of rab3A stimulates inositol 1,4,5-trisphosphate production in digitonin-permeabilized pancreatic acini. (1993) (9)
- Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial (2011) (9)
- Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study (2022) (9)
- Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment (2011) (9)
- Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute‐on‐chronic liver failure and acute decompensation (2020) (9)
- interferon-free Treatment with Faldaprevir, Deleobuvir (bi 207127) and Ribavirin in Sound-c3: 95% Svr12 in Hcv-gt1b : 1102 (2013) (9)
- Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. (2008) (9)
- 51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients (2006) (9)
- Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment. (2000) (9)
- [779] ANTIVIRAL RESPONSE AT WEEK 12 FOLLOWING COMPLETION OF TREATMENT WITH ALBINTERFERON a-2b PLUS RIBAVIRIN IN GENOTYPE 1, IFN-NAIVE, CHRONIC HEPATITIS C PATIENTS (2007) (9)
- No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies (2017) (9)
- Antiviral effect of human recombinant interleukin‐12 in patients infected with hepatitis C virus (2000) (9)
- Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection (2016) (9)
- Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. (2009) (9)
- Functional testing strategy for coding genetic variants of unclear significance in MLH1 in Lynch syndrome diagnosis. (2015) (9)
- Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients (2018) (9)
- 54 COMPLETELY INDIVIDUALIZED TREATMENT DURATIONS (24, 30, 36, 42, 48, 60 OR 72 WEEKS) WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS (INDIV-2 STUDY) (2010) (9)
- Stimulation of inositol 1,4,5-trisphosphate production by peptides corresponding to the effector domain of different Rab3 isoforms and cross-linking of an effector domain peptide target. (1995) (9)
- DNA mismatch repair activity of MutLα is regulated by CK2‐dependent phosphorylation of MLH1 (S477) (2018) (9)
- In vitro activity of biosynthetic human diarginylinsulin (1990) (9)
- Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus. (2000) (8)
- [Expert recommendations: Hepatitis C and transplantation]. (2016) (8)
- Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. (2006) (8)
- Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study (2022) (8)
- Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation (2019) (8)
- Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography. (2019) (8)
- [Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial]. (2009) (8)
- and weight-based ribavirin in patients with genotype (2011) (8)
- Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy. (2008) (8)
- T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219) (2012) (8)
- Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs (2018) (8)
- Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial (2014) (8)
- Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection (2012) (8)
- Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. (1995) (8)
- Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons? (2004) (8)
- Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies (2014) (8)
- P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study (2015) (8)
- Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis (2015) (8)
- Risk factors for early and late procedure‐related adverse events in percutaneous endoscopic gastrostomy: A single center, retrospective study (2018) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- Effect of a Rab3A effector domain-related peptide, CCK, and EGF in permeabilized pancreatic acini. (1994) (8)
- Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy (2012) (8)
- 606 Impaired quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels (2003) (8)
- Randomized trial of albinterferon alfa‐2b every 4 weeks for chronic hepatitis C virus genotype 2/3 (2012) (8)
- Predictors associated with treatment initiation and switch in a real‐world chronic hepatitis B population from five European countries (2014) (8)
- Randomized, controlled trial with interferon-alpha (IFN-alpha) combined with ribavirin with and without amantadine sulfate in primary IFN-alpha nonresponsive patients with chronic hepatitis C (2001) (8)
- 1202 CHARACTERISATION OF HCV VARIANTS IN NON-SVR PATIENTS IN THE REALIZE STUDY SUGGESTS THAT TELAPREVIR EXHIBITS A CONSISTENT RESISTANCE PROFILE IRRESPECTIVE OF A LEAD-IN (2011) (8)
- Frequency of the Amsterdam criteria in a regional German cohort of patients with colorectal cancer. (2002) (8)
- First‐phase parameters in hepatitis C viral kinetics (2002) (8)
- Somatic hypermutation and mRNA expression levels of the BCL‐6 gene in patients with hepatitis C virus‐associated lymphoproliferative diseases * (2007) (8)
- Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis (2020) (8)
- O66 SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS (2014) (8)
- 946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS (2009) (7)
- High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies (2016) (7)
- 479 Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the Hep-Net/international HDV intervention trial (2006) (7)
- Epidermal growth factor inhibits hormone- and fibroblast growth factor-induced activation of phospholipase C in rat pancreatic acini (1995) (7)
- To bead or not to bead: is transarterial chemoembolization with Doxorubicin-eluting beads a new standard of care in hepatocellular carcinoma? (2010) (7)
- 317 International multicenter, randomized, controlled study comparing standard versus dynamically individualized treatment in patients with chronic hepatitis C (DITTO-HCV) project) (2003) (7)
- Low Serum Levels of (Dihydro-)Ceramides Reflect Liver Graft Dysfunction in a Real-World Cohort of Patients Post Liver Transplantation (2018) (7)
- Contrast Enhancement of the Brain by Folate-Conjugated Gadolinium–Diethylenetriaminepentaacetic Acid–Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging (2012) (7)
- Individual invitation letters lead to significant increase in attendance for screening colonoscopies: Results of a pilot study in Northern Hesse, Germany (2018) (7)
- Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras (2016) (7)
- Liver Transplantation in Acute-on-Chronic Liver Failure: Considerations for a Systematic Approach to Decision Making (2018) (7)
- [58] SUSTAINED OFF-TREATMENT HBeAg RESPONSE IN TELBIVUDINE AND LAMIVUDINE TREATED HBeAg-POSITIVE PATIENTS FROM THE GLOBE STUDY (2007) (7)
- Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic? (2021) (7)
- [Endoscopic-retrograde cholangiopancreatography in patients with surgical modification of anatomy]. (2010) (7)
- Detection of microsatellite instability from archival, hematoxylin-eosin-stained colorectal cancer specimen. (2002) (7)
- Pegylated interferon monotherapy for chronic hepatitis C. (2004) (7)
- Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study (2019) (7)
- P1312 SOFOSBUVIR AND DACLATASVIR FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: POTENT ANTIVIRAL ACTIVITY BUT LACK OF CLINICAL BENEFIT IF TREATMENT IS GIVEN TOO LATE (2014) (7)
- Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. (2005) (7)
- Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program (2016) (7)
- Effect of epidermal growth factor on cholecystokinin-induced amylase release and inositol 1,4,5-trisphosphate production in pancreatic acinar cells. (1993) (7)
- Synthetic Rab3A effector domain peptide stimulates inositol 1,4,5-trisphosphate production in various permeabilized cells. (1994) (7)
- Chronic Hepatitis B Treatment Initiation and Modification Patterns in Five European Countries: A 2-Year Longitudinal, Non-Interventional Study (2014) (7)
- All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study (2014) (7)
- [The guidelines program of the DGVS]. (2013) (7)
- Influence of antibiotic-regimens on intensive-care unit-mortality and liver-cirrhosis as risk factor. (2016) (7)
- Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe (2015) (7)
- Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany (2022) (7)
- Feasibility and reproducibility of liver and pancreatic stiffness in patients with alcohol-related liver disease. (2019) (7)
- RNA-binding activity of hepatitis C virus NS4B: a novel target for small molecule inhibitors. (2009) (7)
- Anti-p53 autoantibodies in hepatitis C virus-infected patients. (1997) (7)
- Ribavirin Concentration Determines Treatment success of First-Generation DAA-Based Chronic HCV Therapy (2016) (7)
- Dynamics of hepatitis C virus quasispecies turnover during interferon‐α treatment (2003) (7)
- 798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY (2013) (7)
- GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection: 888 (2016) (7)
- P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL (2014) (7)
- 647 Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors (2014) (7)
- Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry (2021) (7)
- Interleukin-18 is increased only in a minority of patients with active Crohn’s disease (2007) (7)
- OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results (2011) (7)
- 122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH (2010) (6)
- 689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR (2008) (6)
- Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro (2020) (6)
- M1913 Lack of Influence of Baseline Genotype On Antiviral Response in Subjects with Chronic Hepatitis B Infection Receiving Tenofovir Df 300 Mg Qd for 1 Year (2008) (6)
- Interferon-α improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease (2009) (6)
- PREDICTION OF RESPONSE TO PEGINTERFERON-ALFA IN HBEAG POSITIVE CHRONIC HEPATITIS B: A MODEL BASED ON 721 PATIENTS (2008) (6)
- Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B (2014) (6)
- Modulation of TH-1/TH-2 serum cytokine profiles and TNF-receptor response in patients with chronic hepatitis C during interleukin-12 (IL-12) treatment (2000) (6)
- 792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY (2013) (6)
- Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. (2018) (6)
- Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R) (2016) (6)
- Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (2015) (6)
- Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial (2014) (6)
- Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study (2015) (6)
- 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS (2010) (6)
- Capnography monitoring of non‐anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: A prospective, controlled, randomized trial (2020) (6)
- Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site‐directed mutagenesis of an NS4B aminoterminal basic leucine zipper (2012) (6)
- Mixing and matching drugs: what makes sense? (2011) (6)
- Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response. (2021) (6)
- AFP ratio predicts HCC recurrence after liver transplantation (2020) (6)
- Risk Factors and Outcomes Associated with the Carriage of Tigecycline- and Vancomycin-resistant Enterococcus faecium. (2020) (6)
- 503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels (2004) (6)
- Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis (2020) (6)
- Evaluation of 2 D-Shear Wave Elastography for Characterisation of Focal Liver Lesions (2017) (6)
- Predictive Value of Computed Tomography Scans and Clinical Findings for the Need of Endoscopic Necrosectomy in Walled-off Necrosis From Pancreatitis (2017) (6)
- [Current recommendations for the treatment of chronic hepatitis C]. (2014) (6)
- Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study (2020) (6)
- Conversion From Sirolimus to Everolimus in Long‐Term Liver Graft Recipients (2017) (6)
- 1132 HIGH CONCORDANCE BETWEEN SVR12 AND SVR24 IN PATIENTS RECEIVING TELAPREVIR PLUS PEGINTERFERON AND RIBAVIRIN IN THREE PHASE III CLINICAL TRIALS: ADVANCE, ILLUMINATE AND REALIZE (2012) (6)
- Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections (2018) (6)
- 539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS (2012) (6)
- Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection (2019) (6)
- Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection (2018) (6)
- Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia (2020) (6)
- Primary actinomycosis of the liver mimicking malignancy. (2009) (6)
- On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study (2016) (6)
- [88] VIRAL KINETICS DURING 14-DAY TREATMENT WITH DEBIO-025 DEMONSTRATE EFFICIENT BLOCKING OF VIRAL REPLICATION IN DIFFERENT HCV GENOTYPES WITHOUT SIGNS OF EMERGING VIRAL RESISTANCE (2007) (6)
- OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach (2011) (6)
- Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors (2020) (6)
- JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 (2019) (6)
- Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. (2017) (6)
- Effects of agonists on p21ras and ras-related proteins in rat pancreatic acinar cells. (1992) (6)
- Non‐invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)‐associated liver disease and sustained virologic response (SVR): 3 years follow‐up of a prospective longitudinal study (2021) (5)
- 733 Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon Alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection (2006) (5)
- A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial (2014) (5)
- Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon‐alpha 2a plus ribavirin (2008) (5)
- [Postexposure prevention after occupational exposure to HBV, HCV and HIV]. (2003) (5)
- 511 Evaluation of a new, highly sensitive, real time PCR based assay for quantification of HCV RNA (2004) (5)
- Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy (2016) (5)
- 67 Hepatitis C viral kinetics in chronically infected patients treated with the serine protease inhibitor BILN 2061 (2004) (5)
- Preparation of basolateral membrane vesicles from rat enterocytes: influence of different gradient media. (1994) (5)
- ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection (2015) (5)
- 559 Individualized treatment strategy with peginterferon alpha-2b (PEG-IFN a) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients (2006) (5)
- Corrigendum to “SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS”[J Hepatol 42 (2005) 615–624] (2005) (5)
- Favourable and disappointing lessons from viral kinetics. (2002) (5)
- Hepatocellular Carcinoma and Smoking: Oblivion or Contempt? (2013) (5)
- High sustained virologic response rates in hepatitis C virus genotype 3 patients with and without cirrhosis treated with daclatasvir/sofosbuvir or velpatasvir/sofosbuvir ± ribavirin according to baseline resistance analysis (2017) (5)
- Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (5)
- Development of ulcerative colitis after heart transplantation during immunosuppressive therapy. (2005) (5)
- No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. (2013) (5)
- Global timing of hepatitis C virus elimination in high-income countries: an updated analysis (2020) (5)
- Serum Sphingosine‐1‐Phosphate Is Decreased in Patients With Acute‐on‐Chronic Liver Failure and Predicts Early Mortality (2020) (5)
- Analysis of MUTYH alternative transcript expression, promoter function, and the effect of human genetic variants (2019) (5)
- Assessment of initial hexose uptake in adipocytes using the physiological substrate D-glucose. Particular relevance to human adipocytes. (1985) (5)
- P0900 : Consideration of viral resistance for optimization of direct antiviral therapy of chronic hepatitis C (2015) (5)
- Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program (2016) (5)
- 771 DECLINE OF DETECTABLE RESISTANCE MUTATIONS WITHIN THE HCV NS3 PROTEASE QUASISPECIES DURING LONG-TERM FOLLOW-UP AFTER TREATMENT WITH TELAPREVIR (2010) (5)
- [Integrated management of patients with chronic inflammatory bowel disease in the Rhine-Main Region: results of the first integrated health-care project IBD in Germany]. (2013) (5)
- Acoustic Radiation Force Impulse-Imaging for Non-Invasive Assessment of Liver Fibrosis: A Pooled Meta-Analysis (2011) (5)
- Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). (2019) (5)
- Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection (2020) (5)
- O115 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE (2014) (5)
- Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries". (2017) (5)
- Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease (2020) (4)
- Hepatitis C: New therapeutic strategies needed for advanced disease (2009) (4)
- 898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY (2013) (4)
- Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease (2017) (4)
- Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239 (2016) (4)
- Impact of NS 5 A Sequences of Hepatitis C Virus Genotype 1 a on Early Viral Kinetics during Treatment with Peginterferon-a 2 a plus Ribavirin (2007) (4)
- 956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study (2019) (4)
- Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling? (2020) (4)
- [GB virus-C/hepatitis G virus--discovery, epidemiology, diagnosis and clinical relevance]. (1998) (4)
- Impressive Gains in Patient-Reported Outcomes are Observed in Chronic Hepatitis C Patients with or without Cirrhosis who are Treated with Sofosbuvir and Velpatasvir: Results from Astral-1, -2, -3 and-4 (2016) (4)
- [Mutated serine-threonine kinase gene (STK11) is the cause of Peutz-Jeghers syndrome]. (1998) (4)
- Lack of birth defects after paternal exposure to lamivudine. (2002) (4)
- P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1–6 HCV infection (2015) (4)
- 901 ADDING SIMEPREVIR (TMC435) TO PEGYLATED INTERFERON/ RIBAVIRIN DOES NOT INCREASE PATIENT REPORTED FATIGUE IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV INFECTION: RESULTS FROM THE ASPIRE TRIAL (2013) (4)
- Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C (2013) (4)
- Rapid microsatellite analysis of paraffin embedded tumour specimens from patients with hereditary non-polyposis colorectal cancer. (1998) (4)
- [625] NOVEL MODE OF VIRAL DECLINE DURING TELAPREVIR (VX-950) AND PEG-IFN COMBINATION TREATMENT PREDICTED BY A NEW COMBINED INTRACELLULAR AND CELLULAR HEPATITIS C VIRAL DYNAMICS MODEL (2007) (4)
- 848 VIRAL KINETICS DURING TREATMENT WITH A CONTROLLED-RELEASE RECOMBINANT INTERFERON ALFA 2B IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2008) (4)
- No Distal Migration in Unfixed Versus Fixed Cell Structure Covered Self-Expanding Metal Stents for Treatment of Benign Biliary Disease (2015) (4)
- CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C (2011) (4)
- Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) (2017) (4)
- Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B (2008) (4)
- miRNA-26b Downregulation in Peripheral Blood Mononuclear Cells of Patients with Hepatitis C Associated Lymphomas is Restored by Successful Interferon-Free Antiviral Therapy (2019) (4)
- Severe infection with multidrug-resistant Salmonella choleraesuis in a young patient with primary sclerosing cholangitis (2017) (4)
- Therapie der hepatitis C-virus- infektion (2005) (4)
- HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a (2011) (4)
- 932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS (2012) (4)
- Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard inferferon alfa-2a (2001) (4)
- 144 REDUCED DOSE AND DURATION OF PEGINTERFERON ALFA-2B + WEIGHT-BASED RIBAVIRIN IN EUROPEAN AND ASIAN GENOTYPE 2 AND 3 CHRONIC HEPATITIS C PATIENTS (REDD 2/3 TRIAL) (2009) (4)
- Original Articles: Viral HepatitisAdefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients☆ (2003) (4)
- Hepatic sarcoidosis: Clinical characteristics and outcome (2021) (4)
- Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy (2016) (4)
- 1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2 (2013) (4)
- 296 Importance of ribavirin dosage on virological response rates in patients chronically infected with hepatitis C virus and treated with interferon-based combination therapy (2003) (4)
- Acute-on Chronic Liver Failure (ACLF): A distinct clinical syndrome (2012) (4)
- 911 EFFECTIVE TREATMENT OF AMANITA PHALLOIDES INTOXICATION BY FRACTIONED PLASMA SEPARATION AND ADSORPTION (PROMETHEUS) (2011) (4)
- STARTVerso 1 : A randomized trial of faldaprevir plus pegylated interferon / ribavirin for chronic HCV genotype-1 infection q (2015) (4)
- Efficacy and safety of direct‐acting antivirals for hepatitis C in the elderly: A systematic review and meta‐analysis (2019) (4)
- Telaprevir-Based Regimen in Genotype 1 Hepatitis C Virus-Infected Patients With Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results (2011) (4)
- Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study (2015) (4)
- 617 E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: Results of a 15-month, placebo-controlled trial (2006) (4)
- Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome (2006) (4)
- P0873 : Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has minimal impact on health-related quality of life (HRQOL) compared with placebo during 12-week treatment in treatment-naïve adults with chronic Hepatitis C (CHC) (2015) (4)
- Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma (2021) (4)
- Treatment with Telaprevir/PEG-IFN/RBV after 14-day Telaprevir exposure in phase I studies: Results from the phase IIIB C219 rollover study (2013) (4)
- Gradual increase in platelets following sustained virological response among patients with HCV-induced advanced hepatic fibrosis (2013) (4)
- Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection. (2007) (4)
- IL28B gene variants and glucose metabolism in Type 2 Diabetes. (2016) (4)
- Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R) (2020) (4)
- Operative Risk in Patients with Liver and Gastrointestinal Diseases (2007) (4)
- 705 CONTRAST-ENHANCED ULTRASOUND FOR THE DIFFERENTIATION OF BENIGN AND MALIGNANT FOCAL LIVER LESIONS: A META-ANALYSIS AND SYSTEMATIC REVIEW (2012) (4)
- Genetic Background for Development of Resistance Mutations within the HCV Ns3 Protease–Helicase in Direct Acting Antiviral Naive Patients (2014) (4)
- Neutrophil phenotype and function in partial hepatectomy in man (2010) (4)
- 451 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: ANALYSES OF PRE-DEFINED SUBPOPULATIONS IN THE PHASE 3 ADVANCE TRIAL (2011) (4)
- [Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]. (2006) (4)
- [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response]. (2002) (4)
- Synthetic peptides containing a BXBXXXB(B) motif activate phospholipase C-beta1. (1997) (4)
- Hepatitis C viral kinetic models (2003) (4)
- [Chronic hepatitis C : Standard treatment and remaining challenges]. (2018) (4)
- Clinical Practice Guidelines : Management of hepatitis C virus infection European Association for the Study of the Liver ⇑ (2013) (3)
- [Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C]. (2008) (3)
- P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial (2015) (3)
- Viral hepatitis Elimination: Towards a hepatitis free world. (2022) (3)
- 506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS (2013) (3)
- Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients (2011) (3)
- [Long-term follow-up and therapeutic control of a hepatic metastatic acinar cell carcinoma of the pancreas using FDG PET]. (1998) (3)
- 160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
- Sustained Virological Response Improves Overall Survival in Chronic Hepatitis C Patients with Advanced Fibrosis (2011) (3)
- Evaluation of the Integrated Pulmonary Index® during non-anesthesiologist sedation for percutaneous endoscopic gastrostomy (2020) (3)
- Bile microbiome varies by etiology of cholestatic liver disease. (2020) (3)
- Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates (2018) (3)
- Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis (2020) (3)
- Endoscopic findings in patients with eosinophilic esophagitis (2015) (3)
- P1206 ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2014) (3)
- Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment (2010) (3)
- Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis (2022) (3)
- Real‐world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (3)
- P508 VALIDATION OF THE CLIF-CONSORTIUM (CLIF-C) SCORE TO PREDICT MORTALITY OF PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) IN AN EXTERNAL COHORT AND FOR SEQUENTIAL MEASUREMENTS (2014) (3)
- 499 The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2A (PEGASYS®) and ribavirin (COPEGUS®) (2004) (3)
- Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma (2010) (3)
- Efficacy of 6 months treatment with PEG-interferon alpha-2b plus ribavirin (P/R) in patients infected with hepatitis C with genotype 1 of low viral load (G1LVL) (2005) (3)
- Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis (2017) (3)
- 568 Natural history of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels: data from the multinational PEGASYS study (NR 16071) (2003) (3)
- Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety (2019) (3)
- Epidermal growth factor inhibits amylase secretion and activation of phospholipase C in response to calcium-mobilizing secretagogues in rat pancreatic acini. (1994) (3)
- Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants. (2019) (3)
- Distribution and development of the postnatal murine Vδ1 T‐cell receptor repertoire (2010) (3)
- Prolonged retention of prophylactic pancreatic stents is not associated with increased complications. (2019) (3)
- Assessment of D-glucose uptake in isolated human adipocytes. Comparison of two validated and standardized methods. (1989) (3)
- The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C. (2006) (3)
- Tax1BP1 limits hepatic inflammation and reduces experimental hepatocarcinogenesis (2020) (3)
- Reply to “Vitamin D deficiency and HCV chronic infection: What comes first?” (2011) (3)
- Comparison of Envelope 2 CD81 binding regions in PBMC‐derived versus serum‐derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates (2011) (3)
- Multi-center proficiency tests for Lab-MELD score diagnostics to improve the quality and safety for patients awaiting liver transplantation (2014) (3)
- The KRAS p.G13D mutation in patients with metastatic colorectal cancer: a cheat in the orchestra of predictive biomarkers? (2011) (3)
- Interobserver agreement of Thyroid Imaging Reporting and Data System (TIRADS) and realtime elastography for the assessment of thyroid nodules (2013) (3)
- IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis (2017) (3)
- [Characterization and economic impact of medical patients presenting at the emergency department of an university hospital]. (2013) (3)
- [Hereditary non-polyposis colon carcinoma. Syndrome of the cancer family--a neglected disease]. (2008) (3)
- P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS (2014) (3)
- Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome (2017) (3)
- Ip-10 Is Associated With Il28b Variation And Predicts The First Phase Decline Of Hcv Rna And Outcome Of Therapy In Chronic Hepatitis C (2010) (3)
- P0896 : Long-term follow-up analysis of RAVs in HCV NS3, NS5A, and NS5B in daa therapy failure patients (2015) (3)
- A possible role of miRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation (2016) (3)
- Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras (2019) (3)
- TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment. (2002) (3)
- Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation (2015) (3)
- A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction (2020) (3)
- Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates (2021) (3)
- Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade (2023) (3)
- Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity (2021) (3)
- No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens (2017) (3)
- A proposal for an algorithm enhancing transparency and achieving harmonization for patient selection in rescue allocation for liver allografts in Germany (2013) (3)
- Antiviral Targets in HCV (2012) (3)
- In vivo evidence that human atrial natriuretic factor-(99–126) (hANF) stimulates parasympathetic activity in man (2007) (3)
- Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study (2018) (3)
- [Current Guidelines for treatment of hepatitis C. The eradication of HCV as a goal]. (2011) (3)
- Letter: impact of HBV genotypes and PC/BCP mutations on serum HBsAg levels in Chinese HBeAg negative patients—Authors′ reply (2018) (3)
- Differential binding of sulphated insulin to adipocytes and hepatocytes (1984) (3)
- 905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY (2013) (3)
- THU-181-Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study (2019) (3)
- 642 INDIVIDUALIZED TREATMENT DURATION WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN FOR 24, 30 OR 36 WEEKS IN HCV GENOTYPE1-INFECTED PATIENTS WITH UNDETECTABLE HCV-RNA EARLY DURING THERAPY (INDIV-2 STUDY) (2009) (3)
- Diagnostic Yield and Outcomes of Computed Tomography of the Head in Critically Ill Nontrauma Patients (2019) (3)
- The Epidemiology of Acute Liver Failure of a Population-Based Study Including 25 Million State-Insured Individuals (2020) (3)
- O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
- Expression and secretion of the pro‑inflammatory cytokine IL‑8 is increased in colorectal cancer cells following the knockdown of non‑erythroid spectrin αII. (2020) (3)
- 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results (2014) (3)
- Hepatitis C care cascade in the country of Georgia after 2 years of starting national hepatitis C elimination program (2018) (3)
- 504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS (2013) (3)
- Real-World Medical Costs of Antiviral Therapy Among Patients With Chronic Hcv Infection and Advanced Hepatic Fibrosis. (2015) (3)
- Alox12/15 Deficiency Exacerbates, While Lipoxin A4 Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis (2020) (3)
- [Clinical aspects of liver cirrhoses and its complications and diagnostic problems]. (2001) (2)
- 455 HCV VIRAL KINETICS DURING RIBAVIRIN MONOTHERAPY: RESULTS OF A RANDOMIZED PARTIALLY DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL (2011) (2)
- Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study) (2009) (2)
- Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia (2017) (2)
- Pulmonary impairment independently determines mortality in critically ill patients with acute‐on‐chronic liver failure (2022) (2)
- Iron deficiency anaemia and cataracts in a patient with haemochromatosis (2013) (2)
- Therapeutic vaccinationin chronic hepatitis B: qualitative and quantitative analysis of the virusspecific immune response (2001) (2)
- Impact of disease severity on outcome of antiviral therapy in treatment‐naïve patients with chronic hepatitis C (2007) (2)
- 1414 THE CLIF-CONSORTIUM SCORE PREDICTS MORTALITY MORE ACCURATELY THAN THE MELD AND MELD-SODIUM SCORES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CIRRHOSIS WITH AND WITHOUT ACUTE-ON-CHRONIC-LIVER FAILURE (ACLF). (2013) (2)
- Therapie der Hepatitis B und C - Standards 2004 (2004) (2)
- Fast Interpretation of Thromboelastometry and Aggregometry in Patients Suffering from Chronic Liver Disease. (2019) (2)
- Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. (2013) (2)
- Increased renal responsiveness to human atrial natriuretic peptide in patients with active acromegaly (1988) (2)
- Randomized, controlled trial with interferon-alpha plus ribavirin with and without amantadine sulphate in patients with chronic hepatitis C relapsing after previous successful antiviral treatment (2002) (2)
- SPTAN1 Expression Predicts Treatment and Survival Outcomes in Colorectal Cancer (2021) (2)
- 283 HCV PROTEASE INHIBITOR RESTORES INSULIN SENSITIVITY IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2010) (2)
- P0895 : Comparison of three sequencing methods commonly used in hepatitis C virus resistance analysis: population-based vs. clonal vs. ultra deep sequencing (2015) (2)
- Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis (2022) (2)
- THU-051-Establishment of a new animal model for the acute-on-chronic liver failure (2019) (2)
- [Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C]. (2003) (2)
- Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis (2016) (2)
- Dynamics of hepatitis C virus quasispecies turnover during interferon alfa treatment (2003) (2)
- [Postexposure prophylaxis after occupational exposure to HBV, HCV and HIV]. (2004) (2)
- O13 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN EUROPEAN PATIENTS WHO RELAPSED AFTER PREVIOUS INTERFERON-BASED THERAPY: THE PROMISE TRIAL (2014) (2)
- Treatment of acute hepatitis B with lamivudine vs. placebo: A prospective randomized multicenter trial (2013) (2)
- [Diagnostic imaging in liver cirrhosis]. (2001) (2)
- Thyroid dysfunction and virus genotype can predict response to immunotherapy with interferon-2α in chronic hepatitis C (1998) (2)
- Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis (2020) (2)
- MELD-Lactate Predicts Poor Outcome in Variceal Bleeding in Cirrhosis (2022) (2)
- O213: Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment‐naive patients with HCV genotype 1: phase 3 COMMAND‐3 results (2014) (2)
- Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions (2020) (2)
- Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry (2022) (2)
- Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors (2018) (2)
- Viral Hepatitis and Its Complications (2016) (2)
- [123] SUSTAINED VIROLOGICAL RESPONSE RATES WITH PEGINTERFERON a-2a (40 kD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN RANDOMISED CONTROLLED CLINICAL TRIALS ARE REPLICATED IN THE CLINICAL PRACTICE SETTING (2007) (2)
- Meta-analysis of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis (2013) (2)
- [592] NEOPTERIN AND ALT AS MARKERS OF INFLAMMATION IN CHRONIC HEPATITIS C PATIENTS DURING ADMINISTRATION OF THE HCV NS3-4A PROTEASE INHIBITOR TELAPREVIR (VX-950) IN COMBINATION WITH PEGINTERFERON ALFA 2a (2007) (2)
- A randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohns disease: Good safety profile but lack of efficacy (2010) (2)
- IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies (2017) (2)
- Erratum to “The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure” [J Hepatol 2015;62:831–840] (2015) (2)
- Subcellular distribution of small GTP‐binding proteins in the intestinal cell line Caco‐2 (1995) (2)
- Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (>70 Yrs): Results from the German Hepatitis C-Registry (2016) (2)
- Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis (2019) (2)
- Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience (2022) (2)
- Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. (2010) (2)
- Safety of transient elastography in patients with implanted cardiac rhythm devices. (2017) (2)
- Response prediction in chronic hepatitis C by assessment of IP-10 and IL 28 B-related single nucleotide polymorphisms LAGGING (2017) (2)
- ["Liver enzymes"--interpretation of laboratory values]. (2010) (2)
- [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications]. (2011) (2)
- Hypopituitarism in Wilson’s disease resolved after copper-chelating therapy (2021) (2)
- Randomized, controlled trial with interferon-α (IFN-α) combined with ribavirin with and without amantadinsulfat in primary IFN-α non-responders with chronic hepatitis C (2001) (2)
- Investigation of the Wilson gene ATP7B transcriptional start site and the effect of core promoter alterations (2021) (2)
- High Serum Levels of the Interleukin-33 Receptor Soluble ST 2 as a Negative Prognostic Factor in Hepatocellular Carcinoma 1 (2014) (2)
- 529 Real-time elastography for non-invasive assessment of liver fibrosis in chronic viral hepatitis (2006) (2)
- Early occurrence of hepatocellular carcinoma in patients with and without cirrhosis after HCV treatment with direct-acting antivirals. (2018) (2)
- PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure (2019) (2)
- Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation (2022) (2)
- Electronic images of the month. Use of computed tomography with reformatted imaging to identify ingested drug packets. (2010) (2)
- Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program (2013) (2)
- The portal vein as a distinct immunological compartment - A comprehensive immune phenotyping study. (2018) (2)
- NOD2 Risk Variants and Pathological Bacterial Translocation in Decompensated Cirrhosis (2016) (2)
- P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS (2014) (2)
- Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia (2018) (2)
- 1050 TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY (2009) (2)
- Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia (2007) (2)
- [Treatment of Hepatitis C: State of the Art 2018]. (2018) (2)
- Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in european patients who relapsed after previous interferon-based therapy: the promise trial (2014) (2)
- Protein tyrosine phosphorylation in pancreatic acini: differential effects of VIP and CCK. (1997) (2)
- P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES (2014) (2)
- Effects of guanine nucleotides on bombesin-stimulated signal transduction in rat pancreatic acinar cells (1993) (2)
- Not uncommon: HBV genotype G co‐infections among healthy European HBV carriers with genotype A and E infection (2021) (2)
- Commentary: vitamin D deficiency and liver cancer – cause, effect or myth? Authors’ reply (2014) (2)
- FOXO3a Polymorphism rs4946936 and its interaction with vitamin D in differentiated thyroid cancer (2014) (2)
- [Severe acute cholestatic viral hepatitis E in a non-pregnant woman]. (2008) (2)
- Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. (2015) (2)
- Diacylglycerol acyltransferase-1: a critical host factor for hepatitis C virus assembly and potential new drug target. (2011) (2)
- Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study (2020) (2)
- O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 (2014) (2)
- 1022 METABOLIC SYNDROME INCREASES THE RISK OF PRIMARY LIVER CANCER IN THE UNITED STATES (2011) (2)
- Occludin a new HCV entry factor: is the list of essential hepatitis C virus receptors complete? (2009) (2)
- Late-breaking abstracts (2007) (2)
- P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients (2015) (2)
- P1045 ESTIMATING THE PROBABILITY OF RESPONSE TO PEG-INTERFERON THERAPY IN HBeAg-POSITIVE CHRONIC HEPATITIS B: THE EPIC-B STUDY (2014) (2)
- Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers (2020) (2)
- The way forward in HCV treatment — finding the right path (2008) (2)
- Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (1)
- [614] HOST AND VIRAL BASELINE CHARACTERISTICS IN HEPATITIS C NAIVE AND NON-RESPONDER PATIENTS: COMPARISON OF THREE LARGE RANDOMISED MULTINATIONAL TRIALS (2007) (1)
- Final SVR24 Data From the Phase 3 C-Edge Treatment-Naïve Study of Elbasvir (EBR)/Grazoprevir (GZR) in Patients with Chronic HCV Genotype 1, 4 or 6 Infection (2016) (1)
- Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy (2022) (1)
- Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease (2012) (1)
- P0669 : Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha (2015) (1)
- P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY (2014) (1)
- 291 - Long-Term Follow-Up of Patients with Chronic HCV and F2 or F3 Fibrosis after Achieving SVR with Daa-Based Therapy: Results from the Gilead SVR Registry (2018) (1)
- News in Hepatitis C: Report from the 39th Annual Meeting of the European Association for the Study of the Liver (2005) (1)
- 711 SERUM CYTOKINE LEVELS DURING PEG-IFNA-2a +/− ADEFOVIR TREATMENT OF DELTA HEPATITIS: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2008) (1)
- 1165 CLINICAL UTILITY OF THE ARCHITECT HCV AG ASSAY FOR EARLY TREATMENT RESPONSE MONITORING IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION (2012) (1)
- Influence of interferon-alpha on CD81-expression in HCV-positive patients (2000) (1)
- [Hypertransaminasaemia and impaired liver function in a patient with oligosymptomatic celiac disease]. (2001) (1)
- FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study (2019) (1)
- From the Editor's Desk…. (2021) (1)
- Percutaneous endoscopic necrosectomy using an automated rotor resection device in severe necrotizing pancreatitis (2021) (1)
- Improved Platelet Count and Smaller Spleen Size Long After Sustained Virological Response in Chronic Hepatitis C Patients With Advance Fibrosis (2011) (1)
- Correlation of hepatitis B virus genomic variants with HBsAg Titers and HBV-DNA levels in a large European study cohort of patients with chronic hepatitis B (2017) (1)
- New Rat Model of Advanced Non-Alcoholic-Steatohepatitis-Cirrhosis Developing Acute-on-Chronic-Liver failure (2022) (1)
- 62 Safety and Success of Direct Retrograde Cholangioscopy (DRC) by Use of an Ultra-Slim Endoscope - Results of a Multicenter Study (2013) (1)
- Hepatitis B viral dynamics during four weeks of lamivudine: 150 mg versus 600 mg (1998) (1)
- Controlled trial with pegylated interferon-alpha2b plus ribavirin retreatment in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin (2003) (1)
- 931 PREDICTION OF LONG-TERM SURVIVAL IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS USING STANDARD LABORATORY TESTS (2012) (1)
- The presence of liver cirrhosis is a strong negative predictor of survival for patients admitted to the intensive care unit – Cirrhosis in intensive care patients (2021) (1)
- 1092 EFFECTS OF PRE-TREATMENT WITH BEZAFIBRATE FOLLOWED BY STANDARD OF CARE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION AND ELEVATED GGT LEVELS (2012) (1)
- [Post-exposure prevention after occupational exposure to HBV, HCV and HIV]. (2004) (1)
- 1104 ANALYSIS OF VIRAL FACTORS, CLINICAL PARAMETERS AND IL28B ASSOCIATED WITH OUTCOME OF PATIENTS WITH ACUTE HEPATITIS C AND HIV COINFECTION (2012) (1)
- Towards Individualized Antiviral Therapy of Patients Infected with Hepatitis C Virus Genotypes 2 and 3 (2006) (1)
- Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
- Growth differentiation factor (GDF) -15– a novel biomarker to assess the extent of liver fibrosis in patients with chronic liver disease? (2009) (1)
- 1240 ANALYSIS OF COMPLEX MUTATION PATTERNS IN THE HCV QUASISPECIES OF PATIENTS TREATED WITH TELAPREVIR OR BOCEPREVIR (2011) (1)
- Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma. (2022) (1)
- Telaprevir in Combination with Peginterferon and Ribavirin In Genotype 1 HCV Treatment-Naïve Patients, Prior Relapsers and Prior Non-Responders: Pooled Analysis Of PROVE1, PROVE2, PROVE3 and Study 107: 274 (2010) (1)
- Fidaxomicin-the next step? A new narrow-spectrum macrocyclic antibiotic for the management of clostridium difficile infection. (2011) (1)
- A Possible Role of miRNAs as Predicitve Markers for the Recurrence of Hepatocellular Carcinoma After Liver Transplantation.: Abstract# A382 (2014) (1)
- Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump (2022) (1)
- Add on Interferon-Alpha-2a for the treatment of hbeag negative Hepatitis B patients receiving effective nucleos (t)ide therapy: interim results of the prospective multicentre padd-on trial (2016) (1)
- Differentiation of thyroid nodules using Acoustic Radiation Force Impulse Imaging (2012) (1)
- Reply to: 'Evidence recommending antiviral therapy in hepatitis C'. (2014) (1)
- P0194 : Severe 25-hydroxyvitamin D deficiency is associated with infections and mortality in cirrhosis (2015) (1)
- [Difficult-to-treat patients with chronic hepatitis C]. (2006) (1)
- Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2019 (2020) (1)
- Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: results from the Gilead SVR registry (2018) (1)
- Tu1018 Sofosbuvir-Based Regimens for Patients With Hepatitis C Virus Genotype 3 Infection: Summary Results From the VALENCE, LONESTAR-2, and ELECTRON-2 Studies (2015) (1)
- P545 SEVERE 25-HYDROXYVITAMIN D DEFICIENCY IDENTIFIES HCC PATIENTS WITH A POOR PROGNOSIS (2014) (1)
- T-01 OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients (2013) (1)
- Cytoskeletal scaffolding proteins interact with Lynch‐Syndrome associated mismatch repair protein MLH1 (2010) (1)
- Assessment of liver fibrosis with Supersonic Shear Wave elastography (Aixplorer™) in comparison to the transient elastography (Fibroscan®) and Acoustic Radiation Force Impulse (ARFI)-Imaging in patients with chronic liver disease (2013) (1)
- Efficacy of Treatment Using Direct Acting Antiviral Drugs (DAAS) in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma – Real Life Data (2016) (1)
- [Magnetic resonance cholangiopancreatography (MRCP) from a radiological and gastroenterological perspective]. (2009) (1)
- Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study (2005) (1)
- 191 Relationship between early viral kinetics and immune reactivity in chronic hepatitis C (Genotype 1) patients treated with peginterferon-alfa 2A and ribavirin (2003) (1)
- Impact of colonization with multidrug-resistant organisms on antibiotic prophylaxis in patients with cirrhosis and variceal bleeding (2022) (1)
- [Germline mutations of the MSH6 gene in patients with an atypical hereditary nonpolyposis colorectal carcinoma (HNPCC)]. (2000) (1)
- [Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients]. (2009) (1)
- 919 ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY (2013) (1)
- 579 Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by gastroenterologists in private practice (2006) (1)
- A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES (2018) (1)
- Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B. (2003) (1)
- [Pathogenetic germ-line mutation in patients with hereditary nonpolyposis colorectal carcinoma (HNPCC)]. (1999) (1)
- P0528 : Transient elastography is safe in patients with pacemakers and implantable cardioverter-defibrillators (2015) (1)
- 418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
- 812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial (2016) (1)
- [Treatment of hepatitis B and C -- current standards]. (2004) (1)
- O10 Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure; results of the first multicenter randomized trial (GRAFT study) (2021) (1)
- 876 SOLUBLE SERUM CD81 IS ELEVATED IN PATIENTS WITH CHRONIC HEPATITIS C AND CORRELATES WITH ALANINE AMINOTRANSFERASE SERUM ACTIVITY (2012) (1)
- 330 ACOUSTIC RADIATION FORCE IMPULSE-IMAGING FOR NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS: A POOLED META-ANALYSIS (2011) (1)
- [Treatment of hepatitis C]. (2013) (1)
- [Diagnosis of autonomic diabetic neuropathies of the gastrointestinal tract]. (1992) (1)
- Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1 (2021) (1)
- Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma (2022) (1)
- Overview of commercial HBV assays systems. (2004) (1)
- P1011 ACOUSTIC RADIATION FORCE IMPULSE-IMAGING IN COMPARISON TO TRANSIENT ELASTOGRAPHY FOR NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C: A PROSPECTIVE INTERNATIONAL MULTICENTER STUDY (2014) (1)
- P1312 : Alfapump system versus transjugular intrahepatic portosystemic shunt and paracentesis in the treatment of ascites. A multicentre randomised controlled study (AGUA-trial) (2015) (1)
- Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR) (2017) (1)
- P0818 : Analysis of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy (2015) (1)
- Hepatitis C virus non-structural (NS)5A protein and interferon resistance: challenge of simple mutational analyses by a new bio-mathematical model (2002) (1)
- 271 EXTENDED TREATMENT OF TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1-INFECTION AND SLOW RESPONSE TO PEGYLATED INTERFERON-ALFA AND RIBAVIRIN: A META-ANALYSIS (2010) (1)
- 745 eGFR IMPROVEMENT IN CHRONIC HEPATITIS B PATIENTS WITH TELBIVUDINE TREATMENT IS INDEPENDENT OF ANTIVIRAL ACTIVITY (2013) (1)
- Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. (2022) (1)
- On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies (2016) (1)
- STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS * (2005) (1)
- 1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY (2013) (1)
- Interferon (IFN)– g –Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN- a 2a and Ribavirin for Chronic Hepatitis C Virus Infection (2006) (1)
- Reply to Real-time elastography in the assessment of liver fibrosis. (2008) (1)
- Alternative AKT2 splicing produces protein lacking the hydrophobic motif regulatory region (2020) (1)
- Hepatopulmonary syndrome (HPS) in chronic viral hepatitis (1998) (1)
- Characteristics of HBeAg-positive patients chronically infectedwith hepatitis b virus (HBV) who achieved hbsag loss/seroconversion following tenofovir disoproxil fumarate (TDF) treatment (2009) (1)
- Mutations in the MutSa interaction interface of MLH1 can abolish DNA mismatch repair (2006) (1)
- Adding trastuzumab to standard chemotherapy in HER2-positive esophagogastric adenocarcinoma: a further step toward personalized medicine. (2011) (1)
- Overcoming the roadblocks in hepatitis C virus infection. (2014) (1)
- SAT-269-The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who don’t achieve sustained virologic response (2019) (1)
- Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma (2022) (1)
- Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression. (2021) (1)
- 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project) (2004) (1)
- [539] ULTRASOUND EVALUATION OF PERIHEPATIC LYMPH NODES DURING ANTIVIRAL THERAPY WITH THE PROTEASE INHIBITOR TELAPREVIR (VX-950) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2007) (1)
- Hepatitis B patients under oral nucleos(t)ide treatment with intermittent kidney function assessment (The BONIKA-study) – a multicenter, prospective, observational trial (NCT-Nr. 02267473) (2017) (1)
- P1199 RE-TREATMENT WITH TELAPREVIR-BASED TRIPLE THERAPY AFTER TELAPREVIR EXPOSURE IN PHASE 1 STUDIES: DEEP SEQUENCE ANALYSIS FOR PERSISTENCE OF RESISTANT VARIANTS (2014) (1)
- Point Shear‐Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver‐Related Events in Patients With Chronic Viral Hepatitis (2020) (1)
- Investigation of Viral Escape Mutations within HCV P7 during Treatment with Amantadine in Patients with Chronic Hepatitis C (2013) (1)
- P0766 : Epidemiology of viral resistance in genotype 1 infected patients at approval of IFN-free DAA combination therapy of chronic hepatitis C in Germany (2015) (1)
- High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 (2017) (1)
- [Combination therapy for chronic viral hepatitis C]. (2003) (1)
- 52 DESCRIPTION OF AN AUTOMATED LOW-FLOW ASCITES (ALFA) PUMP SYSTEM FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS. PRELIMINARY REPORT (2012) (1)
- [98] EFFECTOR/MEMORY SUBSETS AND FUNCTIONALITY OF CD4/CD8+ T-CELLS DURING POTENT ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B (CHB) (2007) (1)
- The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells (2023) (1)
- 1203 CLONAL SEQUENCING OF HCV NS3 PROTEASE AND HELICASE T CELL EPITOPES IN PATIENTS IMMUNIZED WITH THE THERAPEUTIC HCV VACCINE IC41 (2011) (1)
- Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1 (2017) (1)
- [Indications and possibilities for using an insulin injection device in the treatment of type II diabetes mellitus with intermediate insulin]. (1988) (1)
- Non-invasive assessment of liver fibrosis with Acoustic Radiation Force Imaging and Transient Elastography in chronic viral hepatitis (2013) (1)
- Detection of mutations necessary for HCV replication in the in vitro replicon system in patients with chronic hepatitis C (2003) (1)
- 163 EVALUATION STUDY FOR THE INFLUENCE OF DIAGNOSTIC METHODS FOR BILIRUBIN, CREATININE AND PROTHROMBIN (INR) FOR LABORATORY MELD SCORE CALCULATIONS (2013) (1)
- [Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)]. (2012) (1)
- Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotype 1 infection and elevated GGT levels (2012) (1)
- [Cystic polyposis of the stomach]. (2008) (1)
- [Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (1)
- New Rat Model of Cholestatic Liver Cirrhosis Developing Acute-on-Chronic-Liver failure (2022) (1)
- Acute-on-Chronic Liver Failure (2018) (1)
- [648] CHARACTERISATION OF HCV GENOTYPE 2/3 PATIENTS WITHOUT A RAPID VIROLOGICAL RESPONSE (RVR): OPTIMISING TREATMENT BY PREDICTING SLOWER RESPONDERS TO PEGINTERFERON a-2a (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) (2007) (1)
- Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection? (2008) (1)
- A fractured duodenal self-expanding metal stent in a patient with pancreatic cancer (2014) (1)
- Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy (2019) (1)
- 601 Anti-viral activity of VX-950 resolves expression of an HCV-associated gene signature (2006) (1)
- Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
- Efficacy of Boceprevir / Peginterferon / Ribavirin for HCV G 1 Compensated Cirrhotics : Meta-Analysis of 5 Trials (2014) (1)
- Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts. (2017) (1)
- [The state of health care and health care paths in inflammatory bowel disease (Crohn's disease and ulcerative colitis)]. (2009) (1)
- Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study (2016) (1)
- Treatment of hepatocellular carcinoma with sorafenib - preclinical rational and results of a phase II trial (2007) (0)
- Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis (2020) (0)
- [Blood oncogene detection in patients with colorectal carcinoma]. (1998) (0)
- From the Editor's Desk... (2022) (0)
- Management of HCV genotype 1 non-responders/relapsers: a European perspective. (2010) (0)
- [Chronic hepatitis C: improved cure rates with new approved medications]. (2012) (0)
- Human PDK1 Kinase Domain in Complex with an HM-Peptide Bound to the PIF-Pocket (2016) (0)
- 6.2 Phlebothrombose (2013) (0)
- [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Simeprevir-benefit assessment according to § 35a SGB V the Federal Joint Committee]. (2014) (0)
- Reply (2003) (0)
- Update on viral kinetics and hcv antiviral therapy (2004) (0)
- Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome (2010) (0)
- P0185 : Acute-on-Chronic Liver Failure not associated with bacterial infections. Characteristics, prognosis and importance of systemic inflammatory response (2015) (0)
- The Mortality of Acute-on-Chronic Liver Failure by APASL vs. EASL-CLIF definition: A Multicenter, Retro- spective Cohort Study in Korea (KACLiF Study) (2014) (0)
- Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure (2022) (0)
- Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders (2015) (0)
- 4.3 Leitsymptom (2013) (0)
- Su1600 Indication of Over-the-Scope (OTS)-Clip vs. Self-Expanding Metal Stent (CSEMS) for Upper Gastrointestinal Leakage: Results of a Large Multicentre Study (2014) (0)
- Comparison of short‐course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation (2022) (0)
- Biological effects of sulphated insulin in adipocytes and hepatocytes (1985) (0)
- [New procedures for submission of comments strengthens the professional societies]. (2012) (0)
- EDP-239, A Novel HCV NS5A Inhibitor, Demonstrates Potent Antiviral Activity After a Single Dose Treatment of Genotype 1 HCV Patients. (2015) (0)
- 153 TELAPREVIR BLOOD LEVELS ARE UNALTERED IN PATIENTS WITH CICLOSPORIN AND TACROLIMUS BASED IMMUNOSUPPRESSION AFTER ORTHOTOPIC LIVER TRANSPLANTATION (2013) (0)
- Not uncommon: HBV genotype g co-infection in HBeAg-negative chronic HBV infected patients (2020) (0)
- 398 HCV-associated mixed cryoglobulinemia: Importance of mutations within the HCV E2 region and CD81 expression on peripheral B lymphocytes (2004) (0)
- 494 REAL-WORLD DATA ON TREATMENT MODIFICATION FROM A LONG-TERM OBSERVATIONAL STUDY OF CHRONIC HEPATITIS B PATIENTS FROM 5 EUROPEAN COUNTRIES (2012) (0)
- Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis (2020) (0)
- From the Editor's Desk… (2020) (0)
- Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. (2023) (0)
- From the Editor's Desk... (2022) (0)
- Adrenal myelolipomas in CAH: is there role for ultrasound screening of the adrenal glands? (2012) (0)
- 496 GENOTYPIC RESISTANCE REDUCED TO VERY LOW LEVELS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED OVER 2-YEARS WITH TELBIVUDINE (LDT) WHEN CONSIDERING BASELINE CHARACTERISTICS AND ROADMAP (2012) (0)
- 3.3 Lymphadenopathie (2013) (0)
- PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING—A SYSTEMATIC REVIEW (2008) (0)
- PREVENTION OF ISCHEMIC TYPE BILIARY LESIONS BY ARTERIAL FIRST REPERFUSION IN ORTHOTOPIC LIVER TRANSPLANTATION: 2799 (2010) (0)
- 1349 VIROLOGIC RELAPSE IS HIGHLY CORRELATED WITH RESPONSE AT WEEK 4 AND 12 BUT NOT WITH IL28B GENOTYPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH PEG-INTERFERON/RIBAVIRIN (2011) (0)
- Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria (2018) (0)
- [Therapy of autonomic diabetic neuropathy of the gastrointestinal tract]. (1992) (0)
- Assessing practical identifiability in hepatitis C viral kinetic modeling (2008) (0)
- 348 HOMODIMERIZATION OF THE HEPATITIS C VIRUS NON-STRUCTURAL 4B PROTEIN REQUIRES AN INTACT BASIC LEUCINE ZIPPER (2009) (0)
- Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies (2017) (0)
- 1157 NUCLEOSIDE TRANSPORTER SLC28A2/3 AND SLC29A1/2 GENETICS: PROTECTION AGAINST ANAEMIA IN CHRONIC HEPATITIS C PATIENTS RECEIVING RIBAVIRIN (2011) (0)
- 443 VITAMIN D DEFICIENCY IS FREQUENT IN CHRONIC HEPATITIS C AND AFFECTS THE OUTCOME OF INTERFERON-ALFA BASED THERAPY (2011) (0)
- 489 A COMMON HLA-DPA1 VARIANT IS ASSOCIATED WITH HEPATITIS B VIRUS INFECTION BUT FAILS TO DISTINGUISH ACTIVE FROM INACTIVE CAUCASIAN CARRIERS (2012) (0)
- Optimal screening and linkage to care model to achieve hepatitis C elimination targets in Georgia (2022) (0)
- Inside Front Cover (2019) (0)
- P732 PREDICTIVE VALUE OF THE INTERFERON-LAMBDA 4 GENE (IFN-L4) FOR DIRECT-/ANTIVIRAL TREATMENT IN HEPATITIS C VIRUS INFECTED PATIENTS WITH GENOTYPES 1, 2, 3, AND 4 (2014) (0)
- Presence of only wildtype virus is the strongest determinant of HBV DNA undetectability and HBsAg clearance in HBeAg-positive chronic hepatitis B patients treated with peginterferon (2012) (0)
- O.127 Phase 2b interim (week 12) results of albumin interferon alpha-2b combined with ribavirin in IFN-naïve, genotype 1 chronic hepatitis C infection (2006) (0)
- ["Hepatitis C awareness, searching for it and referral for therapy"]. (2006) (0)
- Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. (2023) (0)
- [The influence of autonomic diabetic neuropathy and human atrial natriuretic peptide on adrenal gland function in postural changes]. (1991) (0)
- From the Editor's Desk…. (2021) (0)
- 4.4 Bartonellose (2013) (0)
- O‐27: Early HCV RNA kinetics predict relapse to sofosbuvir/ribavirin dual therapy (2015) (0)
- 11.9 Pulmonalstenose (2013) (0)
- 488 Virodynamic predictors of treatment response to peginterferon and lamivudine combination treatment of HBeA-positive chronic hepatitis B (2006) (0)
- Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors: 2017 Presidential Poster Award: 970 (2017) (0)
- A method for cleaning and, where appropriate, analysis of nucleic acids from biological samples (1997) (0)
- Multicenter Performance Evaluation of a New TaqMan PCR Assay for Monitoring Human Immunodeficiency Virus RNA Load (cid:1) (2006) (0)
- Editorial: HBsAg serum levels in HBeAg‐negative chronic HBV infection—is it a matter of genotype? Authors’ reply (2018) (0)
- Supplemental Information Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK 1 Protein Kinase (2016) (0)
- T2005 Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B or Peginterferon Alfa-2a (2010) (0)
- Cost analysis of non-medical vs. treatment-related costs in patients with chemotherapy for colorectal cancer (2008) (0)
- 490 SERUM MICRORNA-122 LEVELS IN DIFFERENT GROUPS OF PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION (2012) (0)
- [Individualised treatment of chronic hepatitis C]. (2006) (0)
- T-26 Long-term FU of patients with CHC treated with telaprevir in combination with PEG-IFN alfa-2a and RBV: Interim analysis of the EXTEND study (2011) (0)
- 54 PRESENCE OF ONLY WILDTYPE VIRUS IS THE STRONGEST DETERMINANT OF HBVDNA UNDETECTABILITY AND HBSAG CLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON (2012) (0)
- Progress in the diagnostic imaging and treatment of hepatocellular carcinoma (2007) (0)
- Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/ velpatasvir/voxilaprevir: results from the Frankfurt Resistance Database (2018) (0)
- 4.3 Hyperventilation (2013) (0)
- INCISIONAL HERNIAS FOLLOWING LIVER TRANSPLANTATION - IMPACT OF INCISION AND IMMUNOSUPPRESSION: 1839 (2010) (0)
- IMO 1001 Lymph node detection by ultrasound within the hepatoduodenal ligament in patients with primary biliary cirrhosis (PBC) (1997) (0)
- Title Page / Editorial Board / Contents / Imprint (2016) (0)
- Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS study) (2018) (0)
- PE-056 : The Safety and Tolerability of SOF/VEL/VOX for 8/12 Weeks in >1,000 Patients Treated in the POLARIS Studies: An Integrated Analysis (2017) (0)
- 1325 CHARACTERISTICS OF ACUTE HEPATITIS C IN A HIV-COINFECTED COHORT: ANALYSIS OF IL28B AND VIRAL FACTORS ASSOCIATED WITH OUTCOME (2011) (0)
- Severe 25-hydroxyvitamin D deficiency identifies HCC patients with a poor prognosis (2014) (0)
- Virological response assessment by polymerase chain reaction and transcription mediated amplification in patients with chronic hepatitis C virus treated with peginterferon-alpha 2A (2001) (0)
- Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope (2011) (0)
- 11.5 Mitralstenose (2013) (0)
- 367 DETERMINATION OF APOPTOTIC ACTIVITY IN UNTREATED CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS WITH DIFFERENT BASELINE VIRAL LOAD (2011) (0)
- Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients: Impact on survival and resection rates. (2017) (0)
- SAT-068-Presence of liver cirrhosis is the strongest negative predictor of survival for patients admitted to intensive care unit (2019) (0)
- 885 INTRAHEPATIC MRNA LEVELS OF THE SUPPRESSORS OF CYTOKINE SIGNALLING 1 AND 3 ARE ASSOCIATED WITH CIRRHOSIS BUT NOT WITH TREATMENT RESPONSE IN CHRONIC HEPATITIS C (2012) (0)
- High prevalence of hepatitis C virus (HCV) antibodies in patients visiting the accident and emergency department of the J. W. Goethe University Hospital, Frankfurt/Main (2010) (0)
- THU-049-Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure (2019) (0)
- 10.5 Kyphoskoliose (2013) (0)
- Combined percutaneous retrograde and peroral antegrade esophagoscopy for the treatment of complete upper esophageal obstruction (2015) (0)
- FibroSURE TM and FibroScan ® in relation to treatment response in chronic hepatitis C virus (2011) (0)
- In-hospital falls and fall-related injury in patients with liver-cirrhosis - malnutrition matters (2020) (0)
- 266 TAX1BP1 LIMITS TUMOR FORMATION IN EXPERIMENTAL LIVER CANCER (2011) (0)
- Power-doppler sonographic appearance, autoimmune activity and clinical course of interferon-related thyroid disease during antiviral therapy of hepatitis C (2006) (0)
- Five years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2021 (2022) (0)
- Activation kinetics of D-glucose transport in normal, obese and diabetic patients (1989) (0)
- Management iatrogener Perforationen in der Endoskopie (2016) (0)
- From the Editor's Desk... (2020) (0)
- Liver Transplantation for Chronic HCV Infection in the United States 2002-2014: An Analysis of the UNOS/OPTN Database (2016) (0)
- [Regulated exocytosis: Ca(2+)-sensor in exocrine cells?]. (1999) (0)
- From the Editor's Desk…. (2022) (0)
- 7.2 Akute interstitielle Nephritis (AIN) (2013) (0)
- Hepatitis B: Management of suboptimal response to oral antiviral therapy (2009) (0)
- P.183 HCV NS5A protein and response to IFN α: mutational analysis in 3a genotype chronic hepatitis C patients from India (2006) (0)
- Risk-guided strategy to prevent cytomegalovirus associated complications after liver transplantation (2018) (0)
- From the Editor’s Desk… (2020) (0)
- 1118 DYNAMICS OF HEPATITIS B VIRUS QUASISPECIES HETEROGENEITY AND EARLY VIROLOGIC RESPONSE IN PATIENTS RECEIVING LOW TO MODERATE GENETIC BARRIER NUCLEOSIDE ANALOGS (2011) (0)
- P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS (2014) (0)
- All-trans retinoic acid co-administered with pegylated interferon and ribavirin does not influence viral kinetics in hepatitis C infected patients with previous non-response: Results of the ATRACTION study (2012) (0)
- [Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B]. (2001) (0)
- Health-Related Quality of Life (HRQL) and Health Utilities (HU) of Patients with Chronic Hepatitis C (CH-C) Treated with an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF): 568 (2014) (0)
- Transarterial Chemoembolization before Liver Transplantation in Patients with Hepatocellular Carcinoma - a Single Center Experience: 2278 (2012) (0)
- Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease (2020) (0)
- Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort (2018) (0)
- Mutations within the CD81-binding sites and hypervariable region (HVR) 2 of the envelope (E) 2 protein and correlation with treatment response in HCV infected patients (2002) (0)
- From the Editor's Desk... (2023) (0)
- 2.5 Hiatushernie (2013) (0)
- Non-invasive assessment of liver fibrosis in HIV infected adults with and without HCV / HBV co-infection and exposure to dideoxynucleosides (2010) (0)
- Long-Term Follow-Up of European HBeAg-Negative Chronic Hepatitis B-Infected Patients on Antiviral Treatment (2016) (0)
- 269 DYNAMICS OF APOPTOTIC ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH ALBINTERFERON ALFA-2B OR PEGINTERFERON ALFA-2A (2010) (0)
- Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study (2016) (0)
- Reply (2016) (0)
- 4.16 Listeriose (2013) (0)
- 483 IMPORTANCE OF HCV RNA ASSAY CHARACTERISTICS AND DIFFERENCES BETWEEN ASSAYS FOR RESPONSE GUIDED THERAPY OF CHRONIC HEPATITIS C (2011) (0)
- Sa1029 An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, Bi 207127 and Ribavirin in the Sound-C2 Study (2013) (0)
- Meetings and Conferences (2016) (0)
- AGA AbstractEGF inhibits secretagogue-induced cAMP production and amylase secretion via pertussis toxin-sensitive G proteins in pancreatic acini (1995) (0)
- Development and validation of the CLIF-AD score for the prognosis of patients with acute decompensation of cirrhosis not fulfilling criteria for acute-on-chronic liver failure (ACLF) (2014) (0)
- Editorial Favourable and disappointing lessons from viral kinetics (2002) (0)
- Colonization and infection with carbapenem-resistant non-fermenting gram-negative bacteria are associated with rapid deterioration and mortality in patients with decompensated liver disease (2016) (0)
- THU-163-Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis (2019) (0)
- First 1-year follow up data from the German NAFLD prospective real-life cohort (FLAG study) show low frequencies of lifestyle changes (2020) (0)
- Impact of a shorter replacement interval of plastic stents on premature stent exchange rate in benign and malignant biliary strictures (2022) (0)
- NS5A resistance patterns and treatment outcomes in DAA-naive genotype 1a chronic hepatitis C patients with and without baseline resistance-associated substitutions (2018) (0)
- Safety of add on Interferon-alpha-2a in hepatitis B patients receiving effective nucleos(t)de therapy: Interim results from the German multicenter PADD-ON trial (2014) (0)
- [Generalized hyperpigmentation and malignant acanthosis nigricans. A case of a patient with hereditary hemochromatosis and gastric cancer]. (2005) (0)
- Sofosbuvir and Velpatasvir for Patients with HCV Infection. (2016) (0)
- From the Editor's Desk... (2022) (0)
- 1166 CLINICAL RELEVANCE OF MINIMAL RESIDUAL VIREMIA DETECTED WITH THE ABBOTT REALTIME HCV ASSAY FOR RESPONSE-GUIDED THERAPY WITH PEG-INTERFERON-a/RIBAVIRIN IN PATIENTS WITH HEPATITIS-C-VIRUS GENOTYPE 1 INFECTION (2012) (0)
- Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study) (2016) (0)
- In-hospital falls and impaired nutritional status are independently associated with in-hospital mortality in patients with liver cirrhosis (2022) (0)
- HBV3 O‐29: A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B (NCT01732224) (2015) (0)
- P0335 : Serum long chain ceramides, sphingosine and sphingosine-1-phosphate as novel diagnostic markers in patients with hepatocellular carcinoma (2015) (0)
- Long-term Follow-up of a Hepatic Metastatic Acinus Cell Carcinoma of the Pancreas Using FDG-PET (1998) (0)
- Reply: (2009) (0)
- From the Editor's Desk... (2022) (0)
- [The clinical relevance of the GB virus C/hepatitis G virus]. (1997) (0)
- From the Editor's Desk…. (2020) (0)
- 2.1 Zyanose (2013) (0)
- CYP24A1 haplotypes are associated with differentiated thyroid carcinoma (2010) (0)
- CS4-01 Response-guided Therapy for Chronic Hepatitis C (2009) (0)
- [Choose wisely - a critical assessment]. (2020) (0)
- 5.1 Akute Tracheobronchitis (2013) (0)
- High SVR rates among patients with multiple negative predictive factors across genotypes treated with sofosbuvir-based regimens (2014) (0)
- Impact of Soluble CD 26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (0)
- P0711 : Genome-wide association study of response to sofosbuvir-ribavirin treatment in GT2/3 HCV patients (2015) (0)
- 4.8 Adrenogenitales Syndrom (AGS) (2013) (0)
- New Rat Model of Alcoholic Liver Cirrhosis Developing Acute-on-Chronic-Liver failure (2022) (0)
- Treatment of hepatitis C in primary healthcare in the country of Georgia (2022) (0)
- 2.4 Cholestase (2013) (0)
- The ef fi cacy and safety of direct acting antiviral treatment and clinical signi fi cance of drug – drug interactions in elderly patients with chronic hepatitis C virus infection (2016) (0)
- 809 DYSREGULATION OF MICRO-RNA EXPRESSION IN SPLENIC MARGINAL ZONE LYMPHOMA IN PATIENTS WITH AND WITHOUT CHRONIC HEPATITIS C VIRUS INFECTION (2011) (0)
- T-28 Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study (2012) (0)
- Human PDK1 Kinase Domain in Complex with Allosteric Activator PS171 Bound to the PIF-Pocket (2011) (0)
- From the Editor's desk…. (2021) (0)
- Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies (2016) (0)
- 3.6 Zyanose (2013) (0)
- Studies on insulin receptors of brush-border membranes isolated from human kidney proximal tubule. (1990) (0)
- Future therapies in the management of hepatitis C virus infection (2010) (0)
- Correction: Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells. (2020) (0)
- 1058 Multiple Plastic Stents (MPS) vs. Covered Self-Expandable Metal Stents (cSEMS) for Endoscopic Therapy in Stenosis of the Choledocho-Choledochal Anastomosis After Orthotopic Liver Transplantation: Data From a Randomised Multicentre Trial (2015) (0)
- Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C (2017) (0)
- Su1729 A Randomized Trial of Guidewire Use for Biliary Stricture Cannulation in Endoscopic Retrograde Cholangiopancreatography (ERCP): Superior Success Rate of a New Single Use Guidewire (2014) (0)
- From the Editor's Desk... (2021) (0)
- 5.6 Prognose (2013) (0)
- 5.3 Reizdarmsyndrom (RDS) (2013) (0)
- 1348 VIRAL HETEROGENEITY IN HCV NS5A GENOME IS LOW IN PATIENTS WITH FAVORABLE IL28B GENOTYPES (2011) (0)
- [Glycyrrhizin for the treatment of allergic diseases and chronic hepatitis]. (1998) (0)
- Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program (2018) (0)
- Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations (2015) (0)
- Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. (2021) (0)
- Treatment of Genotype 1 HCV Treatment-Naïve Patients: final results of phase III study ADVANCE (2011) (0)
- Introducing the HCV miniseries. (2020) (0)
- 712 CELL DEATH DYNAMICS DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (2010) (0)
- 310 MARKED SPIROMETRY DECLINE IN PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT WITH ALBINTERFERON ALFA-2B IS SIMILAR TO PEGINTERFERON ALFA-2A (2010) (0)
- 1.1 Definition (2013) (0)
- A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial (2014) (0)
- 426 Dynamics of CD81-expression on lymphocyte subsets during antiviral treatment of patients with chronic hepatitis C (2006) (0)
- Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics (2018) (0)
- DALYs in Chronic Hepatitis C : A Paneuropean Perspective (2010) (0)
- Regulation of IL-22 in a rat model for acute-on-chronic liver failure (ACLF) (2020) (0)
- Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue (2014) (0)
- P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR (2014) (0)
- 1055 SEQUENCE EVOLUTION OF THE HCV NS3/4A PROTEASE DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION (2010) (0)
- Comparison of daily interferon alfacon-1 with standard regimens of thrice weekly interferon Alfacon-1 in patients with chronic hepatitis C â interim results from an ongoing international trial (2001) (0)
- [Natural course and progression of liver cirhosis in patients with hepatitis C]. (1998) (0)
- O‐28: Safety and efficacy of ledipasvir/sofosbuvir for the treatment of hepatitis c infection: interim analysis of a prospective, observational study (2015) (0)
- P66 SVR with telaprevir, peginterferon alfa-2A and ribavirin in HCV patients with well-characterised prior null response, partial response, viral breakthrough or relapse after peginterferon+ ribavirin (2010) (0)
- From the Editor’s Desk… (2001) (0)
- 292 Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C (2006) (0)
- From the Editor's Desk... (2020) (0)
- 2.7 Obstipation (2013) (0)
- 6.3 Thrombophlebitis (2013) (0)
- [interferon-free treatment of hepatitis C: how and when will it become reality? [corrected]]. (2013) (0)
- Contents (2020) (0)
- Concurrent Session 4 – HCV Development and Strategies CS 401 Response-guided Therapy for Chronic Hepatitis C (2009) (0)
- Su1051 Duration of Undetectable HCV RNA in Patients Treated With Faldaprevir-Deleobuvir Interferon-Free Combination Is Associated With SVR (2014) (0)
- Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program (2014) (0)
- [654] PREDICTION OF VIROLOGIC RESPONSE IN HCV GENOTYPE 1A-INFECTED PATIENTS ACCORDING TO AMINO ACID PATTERN IN NS5A USING STATISTICAL LEARNING ALGORITHMS FOR CLASSIFICATION (2007) (0)
- Human PDK1 Kinase Domain in Complex with Adenosine Bound to the ATP-Binding Site (2016) (0)
- 1105 BASELINE CHARACTERISTICS CAN HELP TO PREDICT HEPATIC DECOMPENSATION DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND ADVANCED LIVER CIRRHOSIS (2012) (0)
- IMO 1003 Perihepatic lymph nodes in patients with chronic hepatitis G and C (1997) (0)
- Performing ERCP in elderly people – risk factors and indications (2014) (0)
- Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability (2021) (0)
- Su1398 Direct Retrograde Cholangioscopy (DRC) for Diagnosis of Indeterminate Biliary Lesions (2013) (0)
- PNPLA3 and HSD17B13 gene variants exert opposite effects on fatty liver phenotypes: results from the FLAG cohort (2020) (0)
- M1950 Prospective Evaluation of MYH Germline Variants in 352 Colonoscopy Patients (2009) (0)
- Involvement of the epidermal growth factor receptor in SRC-dependent activation of extracellular-regulated kinases-1 and -2 in pancreatic AR42J cells (2000) (0)
- Human PDK1-PKCiota Kinase Chimera in Complex with Allosteric Compound PS267 Bound to the PIF-Pocket (2014) (0)
- 25-hydroxyvitamin D deficiency is associated with infections and mortality in cirrhosis (2015) (0)
- [Treatment of hepatitis C virus infection]. (2005) (0)
- O111: Non‐invasive assessment of liver fibrosis (2014) (0)
- Computer modeling of the 3D structure of human cytochrome P450c21 in a young woman with late-onset AGS and a new mutation within the steroid-21-hydroxylase gene (2005) (0)
- Significance of HBsAg and HDVRNA levels in patients with delta hepatitis recruited in the Hep-Net/International HDV intervention trial (2006) (0)
- Results of a ten year prospective observational study on acute hepatitis C in HCV-mono- and HIV/HCV-coinfected patients (2022) (0)
- 299 MIRNA EXPRESSION PROFILING OF LASER-MICRODISSECTED LIVER TISSUE FROM PATIENTS WITH HCV ASSOCIATED HCC REVEALS DISTINCT MIRNA-PATTERNS IN FOUR CHARACTERIZED SUB-COMPARTMENTS WITHIN THE TUMOR-INFILTRATED LIVER (2012) (0)
- Steatosis does not affect the result of antiviral treatment in HCV genotype 3 infected patients (2005) (0)
- Interleukin-12 (IL-12) therapy in patients with chronic hepatitis C (1998) (0)
- From the Editor's Desk… (2020) (0)
- 4.4 Glutensensitive Enteropathie (2013) (0)
- Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1 (2017) (0)
- 1214 MECHANISMS FOR KETOAMIDE ESCAPE IN VAL55 VARIANTS OF THE HCV NS3/4A PROTEASE DOMAIN (2012) (0)
- 1350 HOST-SPECIFIC FACTORS INDEPENDENT OF IL28B GENOTYPE PREDICTING TREATMENT OUTCOME OF INDIVIDUALIZED THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION (2011) (0)
- 2.9 Invasive Methoden (2013) (0)
- [Choosing wisely recommendations in gastroenterology]. (2017) (0)
- Health-Economic Evaluation of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Treatment of Chronic Genotype 1 Hcv Infection in Germany (2016) (0)
- O211: With Interferon (2014) (0)
- THU-186-Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-August 2018 (2019) (0)
- Qu antification of fecal carbohydrates near-infrared reflectance analysis by (0)
- Association of common p53 and mdm2 variants with spontaneous and treatment induced viral clearance in patients with chronic hepatitis C infection (2010) (0)
- [Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)]. (2022) (0)
- 738 BONE MINERAL DENSITY AND METABOLISM IN NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C (2008) (0)
- Ambulatory long-term immunoprophylaxis with intramuscular anti-HBS immunoglobulin to prevent hepatitis B reinfection after orthotopic liver transplantation (2000) (0)
- Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection (2014) (0)
- Acute hepatitis C virus infection: a prospective ten-year observational study of HCV-mono and HCV/HIV-coinfected patients (2020) (0)
- SAT-189-GCAC1809-1812TTCT a novel viral quadruple mutation is strongly associated with basal core promotor double mutation and viral load in Hepatitis B e antigen negative chronic hepatitis B virus infected patients (2019) (0)
- From the Editor's Desk…. (2020) (0)
- [Treatment of hepatitis C--update 2005]. (2005) (0)
- response in chronic hepatitis C virus (2011) (0)
- THU-211-Evaluation of point shearwave elastography using acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in HBeAg-negative chronic HBV infection: A prospective longitudinal study (2019) (0)
- 2.2 Spondyloarthritiden (SpA) (2013) (0)
- Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial (2020) (0)
- Workshop report The American Association for the Study of Liver Diseases: new perspectives in the treatment of hepatitis C (2006) (0)
- Interobserver agreement of thyroid imaging reporting and data system and realtime elastography for the assessment of thyroid nodules (2013) (0)
- FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial (2019) (0)
- 287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT (2010) (0)
- Brown tumor of the mandible and osteitis fibrosa cystica in hyperparathyroidism: a rare disease mimicking an osseous metastasized malignancy (2008) (0)
- NEMO catches the FOX. (2011) (0)
- Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1 (2014) (0)
- O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE) (2006) (0)
- THU-050-Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis (2019) (0)
- 799 EFFECTS OF RIBAVIRIN ON NK CELL PHENOTYPE AND FUNCTION IN HEPATITIS C VIRUS INFECTION (2012) (0)
- Interactions with phospholipids and membrane remodeling by nonstructural protein 5A of hepatitis C virus (2021) (0)
- P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin (2006) (0)
- [Chronic hepatitis C virus infection: always treat!--Pro]. (2002) (0)
- Final Results of a roll-over study (107) with Telaprevir, Peginterferon Alfa-2A and Ribavirin in Prior Null Response, Partial Response, Viral Breakthrough or Relapse HCV Genotype 1 Patients After PR (2011) (0)
- [Chronic hepatitis C: new perspectives in therapy]. (2004) (0)
- 954 – Chronic Hepatitis C (CHC) Patients Who Do Not Achieve Sustained Virologic Response (SVR) Experience Worsening of Their Health-Related Quality of Life (HRQL) (2019) (0)
- 416 PREDICTION OF ACTIVE HBV-CARRIER STATUS IN A COHORT OF EUROPEAN UNTREATED HBeAg NEGATIVE PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (2013) (0)
- 4.5 Morbus Whipple (Lipodystrophia intestinalis) (2013) (0)
- THU-143-High effectiveness of elbasvir/grazoprevir treatment in patients with HCV genotype 1a infection in German real-world: Results from the German hepatitis C registry (DHC-R) (2019) (0)
- Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R) (2018) (0)
- Subcellular distribution and function of the low molecular mass GTPase Rab3A and Rab3B in AR42J cells (1998) (0)
- From the Editor's Desk…. (2020) (0)
- Screening for HNPCC-focussing on families (1999) (0)
- P0721 : Viral and host parameters in association with outcome of acute hepatitis C in HIV-coinfected patients (2015) (0)
- From the Editor's Desk... (2022) (0)
- New Antiviral Therapies in the Management of Hepatitis C Virus Infection (2011) (0)
- [Revolution in the treatment of hepatitis C -- how to adopt the guidelines afterwards?]. (2014) (0)
- P1059 : Severity of coronary artery disease is associated with non-alcoholic fatty liver disease (2015) (0)
- HBV2 O‐31: Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany and the major role of hepatitis B e antigen expression in disease severity and progression (2015) (0)
- 971 MOLECULAR MECHANISMS OF CROSS-RESISTANCE IN PEPTIDOMIMETIC PROTEASE INHIBITORS FOR STAT-C (2009) (0)
- Prevalence and Clinical Impact of Sinusitis in Liver Graft Recipients (2019) (0)
- The effect of peginterferon alfa-2a (40 KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (2003) (0)
- 4.8 Chlamydien-Infektionen (2010) (0)
- 3.1 Transplantation (2013) (0)
- 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin (2016) (0)
- Contents (2020) (0)
- [In Process Citation]. (2014) (0)
- 616 EFFECT OF RIBAVIRIN ON THE FREQUENCY OF RNASE L CLEAVAGE SITES WITHIN THE HEPATITIS C VIRAL GENOME (2009) (0)
- Comprehensive analysis of NK cell phenotype and function during the initial phase of antiviral therapy: distinct roles of Ribavirin and Interferon alpha (2013) (0)
- Whole-genome sequencing of carbapenem-resistant gram-negative bacteria in patients with cirrhosis (2021) (0)
- From the Editor’s Desk… (2022) (0)
- 5.2 Leitsymptom: Splenomegalie (2013) (0)
- CKD / Human studies (2011) (0)
- The predictive role of Week 8 (RVRw8) viral kinetics in prior PR null responders receiving telaprevir in the delayed-start arm of the REALIZE trial (2014) (0)
- Su1608 No Distal Migration in Unfixed vs. Fixed Cell Structure Covered Self-Expanding Metal Stents for Treatment of Benign Biliary Disease (2015) (0)
- 751d SVR Results of Prove3, a Phase 2B Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-Response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/B and Ribavirin Therapy (2009) (0)
- Author response: Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes (2019) (0)
- 9.1 Definition (2013) (0)
- The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection (2022) (0)
- Contents (2020) (0)
- Protein in Response to IFN-Expression and Release of IL-18 Binding (2001) (0)
- Molecular characterization of the cancer-associated MLH1 mutation Asp132His (2006) (0)
- [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (0)
- Selective targeting of tumor-associated macrophages in hepatocellular carcinoma (2015) (0)
- 417 Subgenomic hepatitis C replicon deriving from a clinical isolate with virologic non-response to IFN-based therapy and IFN resistance in vitro (2006) (0)
- From the Editor's Desk... (2020) (0)
- From the Editor’s Desk… (2001) (0)
- P.285 Differences in virus and host characteristics between patients with HCV genotype 2 or 3 participating in a large international study (2006) (0)
- Management of hepatitis C in primary healthcare in the country of Georgia (2020) (0)
- Structure and allosteric effects of activating compounds on protein kinase PDK1 (2010) (0)
- Interleukin-12 (IL-12) treatment in chronic hepatitis C (1998) (0)
- 435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA (2013) (0)
- S1936 Health-Related Quality of Life (HRQOL) with Albinterferon Alfa-2b Plus Ribavirin in IFN Treatment-NaïVe Patients with Genotype 1 Chronic Hepatitis C (2008) (0)
- 7.3 Ileus (2013) (0)
- 439 Hepatitis C viraemia inhibits dendritic cell functions and their ability to induce adaptive immune response to HCV (2006) (0)
- 1006 Viral kinetics in chronically HCV infected patients with persistently normal or elevated ALT levels (2003) (0)
- [Postexposure prevention after occupational exposure to HBV, HCV and HIV]. (2003) (0)
- 618 Prediction for treatment outcome in HCV type 1-infected patients: GAMMA-glutamyltranspepdidase (GGT) is the most reliable independent single parameter (2006) (0)
- Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01 (2022) (0)
- Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial (2012) (0)
- P0728 : Investigation of genetic recombination of hepatitis C virus in patients infected with genotypes 1, 2 and 4 (2015) (0)
- 5.3 Lungenemphysem (2013) (0)
- Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry (2020) (0)
- 5.1 Definition (2007) (0)
- Individualised Treatment of hepatitis C (2007) (0)
- From the Editor's Desk (1957) (0)
- The emerging role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses (2017) (0)
- From the Editor's Desk... (2021) (0)
- P699 PREDICTORS OF HEPATIC STEATOSIS IN A PROSPECTIVE STUDY OF EUROPEAN UNTREATED HEPATITIS B SURFACE ANTIGEN (HBsAg) CARRIERS: EVALUATION BY CONTROLLED ATTENUATION PARAMETER (CAP) (2014) (0)
- PharmaNews (2016) (0)
- A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial (2008) (0)
- Computational Analysis of the Hepatitis C Virus Non-Structural Protein 4B and Functional Implications (2005) (0)
- Human PDK1 Kinase Domain in Complex with Allosteric Compound PS182 Bound to the PIF-Pocket (2012) (0)
- O112: HCV genome sequencing: what the clinician needs to know (2014) (0)
- 420 Dynamics of intra-individual HCV variants during antiviral treatment with peginterferon α and ribavirin (2006) (0)
- P720 HEALTH-RELATED QUALITY OF LIFE (HRQL) AND PATIENT-REPORTED OUTCOMES (PROS) ASSESSMENT IN CHRONIC HEPATITIS C (CH-C) TREATED WITH SOFOSBUVIR (SOF) AND RIBAVIRIN (RBV): THE VALENCE STUDY (2014) (0)
- From the Editor's Desk…. (2020) (0)
- [596] GENOTYPE-SPECIFIC ASSESSMENT OF PREDICTIVE FACTORS FOR SUSTAINED VIROLOGIC RESPONSE AFTER STANDARD TREATMENT IN PATIENTS CHRONICALLY INFECTED WITH HCV (2007) (0)
- P.09.14 FEASIBILITY AND REPRODUCIBILITY OF NON-INVASIVE LIVER AND PANCREATIC STIFFNESS ASSESSMENT IN A COHORT OF PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE (2018) (0)
- Comprehensive analysis of different phases of chronic Hepatitis B Infection (2022) (0)
- Su1382 Endoscopic Treatment of Malignant Biliary Stricture by Intraductal Radio-Frequency Ablation (RFA) - Safety Concerns From a Pilot Study (2013) (0)
- Angled-tip vs. straight-tip guidewire in ERCP: a randomized, multicenter study (2022) (0)
- New aspects of treatment of chronic hepatitis C (2008) (0)
- [230] META-ANALYSIS OF THE PERFORMANCE OF FIBROSCAN FOR THE STAGING OF LIVER FIBROSIS (2007) (0)
- Mutations within the HCV Genotype 1b NS4B Protein and Correlation to Viral Replication and Initial Viral Kinetics During Interferon-alfa-Based Therapy (2005) (0)
- Functional characterization of MLH1 missense variants unveils mechanisms of pathogenicity and clarifies role in cancer (2022) (0)
- Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication (2017) (0)
- 2.2 Dyspnoe (2013) (0)
- [Interferon-alpha plus ribavirin combination therapy in chronic hepatitis C]. (1999) (0)
- Neopterin and ALT as markers of inflammation in chronic hepatitis C patients during administration of the HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa 2a (2008) (0)
- Transabdominal ultrasonography to reduce the burden of X‐ray imaging in prophylactic pancreatic stent localization after ERCP—A prospective trial (2021) (0)
- 23 The effect of peginterferon alfa-2a (40KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (MIPD) (2003) (0)
- 620 Presence of CD4-positive cells in the portal tract on pretreatment liver biopsy is associated with early viral reduction during antiviral treatment of HCV (2006) (0)
- Prof. Dr. med. Peter Galle (2014) (0)
- 754 IMPACT OF RIBAVIRIN ON SUBGENOMIC HEPATITIS C VIRUS RNA DECAY DURING TREATMENT WITH INTERFERON ALFA AND THE PROTEASE INHIBITOR TELAPREVIR (2010) (0)
- PS-086-Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity (2019) (0)
- Transmission of hepatitis C virus in patients undergoing chronic haemodialysis (1993) (0)
- Reply to the letter to the editor "Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a". (2016) (0)
- Novel experimental animal models for acute decompensation and acute-on-chronic liver failure (2020) (0)
- Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts (2022) (0)
- 1364 DEEP SEQUENCING REVEALS ACCUMULATION OF VIRAL VARIANTS IN HCV GENOTYPE 1 INFECTED PATIENTS DURING RIBAVIRIN MONOTHERAPY (2011) (0)
- [457] HCV INFECTION OF DENDRITIC CELLS AFFECTS THEIR FUNCTION LEADING TO AN IMPAIRED ADAPTIVE IMMUNE RESPONSE (2007) (0)
- P725 IMPACT OF THE rs8099917 SNP ON SVR12 IN PATIENTS WITH HCV GT-1 INFECTION TREATED WITH FALDAPREVIR, DELEOBUVIR AND RIBAVIRIN (2014) (0)
- 4.15 Leptospirosen (2013) (0)
- IMO 1002 Perihepatic lymph node volume is related to HCV-viremia but not to genotype (1997) (0)
- Direct Antiviral Combination Treatment According to Presence of Baseline Ravs in NS3, NS5A and NS5B Leads to High SVR Rates in Non-Cirrhotic and Cirrhotic Genotype 1 Infected Patients (2016) (0)
- 27.5 Hypothyreose (2011) (0)
- [Treatment of severe chronic constipation: differential roles of conventional laxatives and the prucalopride prokinetic]. (2011) (0)
- Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (0)
- Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study: 364 (2013) (0)
- Comprehensive analysis of the different phases of chronic hepatitis B virus infection (2022) (0)
- Impact of chronic liver disease on mortality and severity in community-acquired pneumonia (CAP) – Results from the German Competence Network CAPNETZ (2020) (0)
- From the Editor's Desk... (2022) (0)
- Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury (2022) (0)
- N-terminus of hMLH 1 confers interaction of hMutL a and hMutL b with hMutS a (2003) (0)
- 23.3 Kollagenosen (2011) (0)
- 5.4 Enterokolitiden (2013) (0)
- 13.1 Akutes Abdomen (2007) (0)
- 4.6 Brucellosen (2013) (0)
- HCV3 O‐30: The efficacy of antiviral therapy in HCV associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis (2015) (0)
- Colonization with multidrug‐resistant organisms is associated with impaired survival of patients with surgically resected cholangiocarcinoma (2022) (0)
- Market uptake of pegylated interferons for the treatment of hepatitis C in Europe : meeting abstract (2008) (0)
- O212: Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1‐infected patients: the Phase III ATTAIN study (2014) (0)
- [66] MOLECULAR BASIS FOR VX-950 RESISTANCE (2007) (0)
- 1074 INFLUENCE OF NICOTINE ABUSE ON FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (2010) (0)
- Series : Host-pathogen interactions Emerging therapies for the treatment of hepatitis C (2013) (0)
- 776 GENETIC DIVERSITY IN THE LIGAND-BINDING SITE OF THE NS3.4A PROTEASE AND IMPACT ON PEPTIDOMIMETIC INHIBITORS IN HCV-1A (2010) (0)
- Advanced chronic hepatitis C: How to handle if you cannot halt? (2009) (0)
- Acoustic Radiation Force Impulse Imaging der Schilddrüse (2011) (0)
- From the Editor's Desk... (2021) (0)
- 416 LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND TRANSIENT ELASTOGRAPHY IN RELATION TO VIROLOGIC RESPONSE: A SUBSTUDY OF THE PHASE 3 ALBINTERFERON ALFA-2B TRIALS (2010) (0)
- 5.3 Pathogenese (2013) (0)
- Dicer Prevents Hypoxia-Induced Up-Regulation of HIF-1A, Hypoxic Response and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma (2016) (0)
- 820 CD81 EXPRESSION ON LYMPHOCYTE SUBTYPES FOR DISCRIMINATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND RELAPSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEG-INTERFERON-ALFA AND RIBAVIRIN (2011) (0)
- CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients (2023) (0)
- Prevalence of hepatitis C virus subtypes in Germany (1993) (0)
- Human PDK1 Kinase Domain in Complex with Allosteric Activator PS114 Bound to the PIF-Pocket (2011) (0)
- Safety and efficacy of twice daily versus every 8 hour telaprevir with Peginterfepon/Ribavirin (PR) in patients with cirrhosis (2013) (0)
- 819 THE BASIC LEUCINE ZIPPER MOTIF OF THE HEPATITIS C VIRUS NONSTRUCTURAL PROTEIN 4B IS ESSENTIAL FOR REPLICATION EFFICACY IN A GENOTYPE IB REPLICÓN MODEL (2011) (0)
- DNA mismatch repair activity of MutLα is regulated by CK2-dependent phosphorylation of MLH1 (S477) Abbreviated title: Phosphorylation of MLH1 (2018) (0)
- Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
- T1971 Influence of Nicotine Abuse on Fibrosis Progression in Chronic Hepatitis C Virus (HCV) Infection (2010) (0)
- PIN80 Multivariate Cox Analysis Regarding Treatment Switch on Chronic Hepatitis B (CHB) Disease Management Based on a 2-Year Prospective Study in 5 European (EU) Countries (2012) (0)
- 44 Was sind Interferone (2004) (0)
- Intercellular crosstalk regulating ARRB2/RARRES1 is involved in transition from fibrosis to cancer (2021) (0)
- Su1058 Early Stopping Rules for Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Exploratory Study of Pooled Data From Phase III Trials (2014) (0)
- Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes (2018) (0)
- FRI-207-Subgroup analysis of patients undergoing switch of nucleos (t)ide regimen for HBV treatment during the prospective BONIKA trial (2019) (0)
- From the Editor's Desk…. (2020) (0)
- Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB) (2009) (0)
- P1309 HCV MUTANTS RESISTANT TO MACROCYCLIC NS3-4A PROTEASE INHIBITORS SUPPRESS INTERFERON-β INDUCTION BY EFFICIENT MAVS CLEAVAGE (2014) (0)
- Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients – authors' reply (2015) (0)
- 320 TREATMENT RESPONSE TO SORAFENIB CORRELATES TO DISTINCT TUMOUR MICRO RNA CLUSTERS IN HEPATOCELLULAR CARCINOMA (2012) (0)
- IMO 1004 Echopattern of the liver in patients with chronic hepatitis C (1997) (0)
- P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies (2017) (0)
- Mass Drug Administration for Scabies Control (2016) (0)
- Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry (2022) (0)
- Usage of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease (2018) (0)
- 311 Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment (2010) (0)
- The Role of Small Molecular Weight GTP-Binding Proteins in Stimulus Secretion Coupling of Pancreatic Acinar Cells (1993) (0)
- [Gangliocytic paraganglioma--a rare differential diagnosis of a submucosal duodenal tumor]. (2011) (0)
- 376 SOLUBLE CD163 IS ASSOCIATED WITH LIVER INFLAMMATION AND FIBROSIS IN CHRONIC HEPATITIS B VIRUS INFECTION (2013) (0)
- Human PDK1 Kinase Domain in Complex with Compound PS653 Bound to the ATP-Binding Site (2016) (0)
- HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients (2018) (0)
- Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. (2017) (0)
- 546 Early HCV-RNA decline in peripheral blood mononuclear cells predicts SVR versus relapse in chronic hepatitis C patients treated with pegylated interferon-α plus ribavirin (2006) (0)
- Contrast-enhanced ultrasound of adrenal mass: differentiation between benign and malignant lesions (2008) (0)
- 1.3 Leitsymptome (2013) (0)
- Contents (2020) (0)
- Abstract B39: Inhibition of the oncoprotein FUBP1 by SN-38 represents a novel therapeutic option for the treatment of hepatocellular carcinoma (2016) (0)
- Evaluation of 2D-shear wave elastography for characterisation of focal liver lesions running title: 2D-SWE and liver lesions (2016) (0)
- O113: Association of the −515A>G CDC6 polymorphism with risk to develop hepatocellular carcinoma in patients with chronic hepatitis C (2014) (0)
- 6.2 Aspergillose (2013) (0)
- 848b TMC435 in Patients Infected with HCV Genotype 1 Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Virologic Analyses of The ASPIRE Trial (2012) (0)
- Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis (2018) (0)
- [Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis]. (2005) (0)
- Significance of elevated IL8 levels in patients with chronic hepatitis C in comparison with patients with liver diseases of different origin (2003) (0)
- 826 SAFETY AND EFFICACY OF TWICE DAILY VERSUS EVERY 8 HOUR TELAPREVIR WITH PEGINTERFERON/RIBAVIRIN (PR) IN PATIENTS WITH CIRRHOSIS (2013) (0)
- Clinical and virological characteristics of patients with chronic hepatitis C virus (HVC) infection and failure to multiple direct acting antiviral (DAA) therapies (2017) (0)
- 719 A CROSS-SECTIONAL ANALYSIS OF CHRONIC HEPATITIS B PATIENT CHARACTERISTICS AND CLINICAL MANAGEMENT PATTERNS IN GERMANY, POLAND, ROMANIA AND TURKEY (2010) (0)
- 11.2 Nierentransplantation (NTX) (2013) (0)
- 694 HLA CLASS I ALLELES ASSOCIATED WITH HCV POLYMORPHISMS AND RESPONSE TO ANTIVIRAL THERAPY IN HCV GENOTYPE 1-INFECTED PATIENTS (2010) (0)
- 4.3 Myeloproliferative Neoplasien (MPN) (2013) (0)
- [658] OPTIMAL PRE-TREATMENT HCV-RNA LEVEL FOR PREDICTION OF SVR WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN IN GENOTYPE 1 PATIENTS: GENERALISED ADDITIVE LOGISTIC REGRESSION MODEL (GAM) ANALYSIS (2007) (0)
- S812 Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials (2022) (0)
- Chronic hepatitis C virus infection: a general indication for treatment! - Pro (2002) (0)
- Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) (2022) (0)
- 11.2 Aortenstenose (2013) (0)
- 6560 POSTER A Phase I Safety and Pharmacokinetic Study of Everolimus, an Oral mTOR Inhibitor, in Subjects With Impaired Hepatic Function (2011) (0)
- From the Editor’s Desk… (2021) (0)
- 2.5 Ödeme (2013) (0)
- 46 Was sind pegylierte Interferone (2004) (0)
- 9.4 Pathogenese (2013) (0)
- P483 CK 18 BASED SERUM APOPTOTIC CELL DEATH MARKER M30 PREDICTS SURVIVAL IN PATIENTS WITH LIVER CIRRHOSIS (2014) (0)
- THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment (2019) (0)
- From the Editor's Desk... (2021) (0)
- High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R) (2019) (0)
- Hepatitis B Virus Precore-, Basal Core Promotor- and Pres-Gene Variants: Importance for Reactivation in a Large Cohort of HBS Antigen Carriers (2016) (0)
- From the Editor's Desk... (2021) (0)
- [Treatment of parenterally transmittable viral hepatitis]. (2022) (0)
- P698 CLINICAL OUTCOME AFTER 2 YEARS FOLLOW-UP IN A COHORT OF EUROPEAN UNTREATED HEPATITIS B (HBV) INFECTED PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (ALBATROS STUDY) (2014) (0)
- Enzymatic and antisense-effects of a specific anti Ki-ras ribozyme in vitro and in cell culture (1998) (0)
- Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?" (2018) (0)
- P1120 PREDICTION OF SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH TELAPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PHASE 3 TRIALS (2014) (0)
- P0189 : Proton Pump Inhibitor treatment is associated with increased mortality in patients with cirrhosis (2015) (0)
- Free Paper Session III (2006) (0)
- [Use of Thrombopoetin-Receptor-Agonists (TPO-RA) in patients with liver cirrhosis before invasive procedures]. (2022) (0)
- P683 INFLUENCE OF A NTCP RECEPTOR GENE POLYMORPHISM ON HEPATITIS B VIRUS (HBV) INFECTION (2014) (0)
- Delayed activation of D-glucose transport in type II diabetes mellitus. (1992) (0)
- [624] ALBUMIN INTERFERON ALFA-2b DOSED AT Q2W OR Q4W INTERVALS DEMONSTRATES COMPARABLE WEEK 12 EFFICACY RESPONSE IN IFN NAIVE, GENOTYPE-1 RAPID VIRAL RESPONDERS (2007) (0)
- 7.10 Kardiopulmonale Reanimation (2013) (0)
- Inhibition of the oncoprotein FUBP1 by SN-38 represents a novel therapeutic option for the treatment of hepatocellular carcinoma (2016) (0)
- Response to Braillon. (2013) (0)
- Hepatic and portal vein flow in correlation with intrahepatic fat deposition and liver histology (1998) (0)
- Diversity of amino acid sequences within the HCV E2 protein in serum and PBMC (2009) (0)
- 819 HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ALBINTERFERON ALFA-2B PLUS RIBAVIRIN IN IFN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (2008) (0)
- 6.2 Transfusionstherapie (2013) (0)
- 598 HOMOGENEOUS VIRAL DYNAMICS IN HETEROGENEOUS QUASISPECIES POPULATIONS IN HCV RESPONDERS TO STANDARD IFN THERAPY (2008) (0)
- 4.1 Definition (2013) (0)
- [44-year-old patient with fulminant liver failure]. (2003) (0)
- NS5A inhibitors to treat hepatitis C virus infection. (2012) (0)
- 298 ESCITALOPRAM FOR THE PREVENTION OF PEG-IFN-α AND RIBAVIRIN ASSOCIATED DEPRESSION IN HCV-INFECTED PATIENTS: FINAL RESULTS FROM THE CIPPAD-TRIAL (2010) (0)
- Hepatitis C Virus Genotype 3: Hope for Nonresponders and Patients With Cirrhosis (2014) (0)
- [430] RIBAVIRIN ACTS AS HEPATITIS C VIRUS MUTAGEN ON NONSTRUCTURAL 5B QUASISPECIES IN VITRO AND DURING ANTIVIRAL THERAPY (2007) (0)
- Characterization of HBsAg decline by genotype in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumurate (TDF) for up to 4 years (2011) (0)
- From the Editor's Desk…. (2021) (0)
- Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
- Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells (2020) (0)
- 813 TELAPREVIR SERUM LEVELS DURING TREATMENT FOR HCV GT1 INFECTION ARE ASSOCIATED WITH EXTENDED RAPID VIROLOGIC RESPONSE BUT DO NOT AFFECT HEMOGLOBIN DECLINE (2013) (0)
- Reply: (2005) (0)
- From the Editor's Desk... (2022) (0)
- 578 Comparison of RT-PCR and TMA-based assays for detection of HCV RNA in formalin fixed paraffin-embedded liver tissue samples (2003) (0)
- Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01 (2022) (0)
- P6: Prevalence of HCV, HBV and HIV infections among hemophiliac (2014) (0)
- IMO 1205 Flow pattern in the right hepatic vein reflects fatty infiltration of the liver in patients with chronic hepatitis C (1997) (0)
- 13.3 Schock (2013) (0)
- Acoustic radiation force impulse imaging of thyroid gland (2011) (0)
- Hepatitis C Virus-Infektion und Lichen planus (1998) (0)
- 1.5 Geriatrische Rehabilitation (2013) (0)
- 1.11 Leberzirrhose (2013) (0)
- 4.9 Cholera (2013) (0)
- Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center. (2022) (0)
- 1089 ASSOCIATION OF COMMON P53 AND MDM2 VARIANTS WITH SPONTANEOUS AND TREATMENT INDUCED VIRAL CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2010) (0)
- OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study (2011) (0)
- Su1064 Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the Valence Trial (2014) (0)
- Gestörte Sekretions- und Resorptionsmechanismen bei Diarrhö (1994) (0)
- Hepatitis C virus (HCV) genotypes 2 3 infection: A curable disease (2003) (0)
- SAT-133-2D-Shear-Wave elastography predicts survival in advanced chronic liver disease (2019) (0)
- The American Association for the Study of Liver Diseases: New Perspectives in the Treatment of Hepatitis C (2006) (0)
- Decline In Pulmonary Physiology During Treatment Of Chronic Hepatitis C With Long-Acting Interferons And Ribavirin (2011) (0)
- 950 PK-PD MODELING OF VIRAL KINETICS WITH UPCOMING RESISTANCE SIMULATING COMBINATION THERAPY OF LONG-ACTING INTERFERONS AND STAT-C IN HCV PATIENTS (2009) (0)
- From the Editor's Desk... (2022) (0)
- 893 VARIATIONS OF VITAMIN D LEVELS IN GENOTYPE 1HEPATITIS C PATIENTS UNDERGOING ANTIVIRAL THERAPY CORRELATE WITH STAGE OF FIBROSIS BUT NOT WITH TREATMENT OUTCOME (2012) (0)
- STEROID-FREE IMMUNOSUPPRESSION FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION USING A ONCE-DAILY BASED FORMULATION OF TACROLIMUS: 2802 (2010) (0)
- 9.1 Pneumothorax (2013) (0)
- Multiple HCV Amino Acid Variants Associate with Interferon Lambda Polymorphism in Genotype 1a, 1b and 3a Infections (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stefan S. Zeuzem?
Stefan S. Zeuzem is affiliated with the following schools: